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Abstract 
 ARGLU1 is a well conserved protein whose function is not well understood.  I will show 
that ARGLU1 is an alternatively spliced gene, with at least three alternatively spliced isoforms.  
The main isoform codes for a nuclear protein that has been associated with the mediator 
transcriptional regulation complex as well as components of the spliceosome. One alternative 
isoform of ARGLU1 retains a single unspliced intron, even though all other introns have been 
removed, and is localized exclusively in the nucleus. A second alternative isoform causes inclusion 
of a premature termination codon, and is quickly degraded by the nonsense mediated decay quality 
control pathway.  Interestingly, the retained intron contains an ultraconserved element, which is 
more than 95% conserved between human and chicken for over 500 bases.  I will show that this 
ultraconserved element plays a key role in the alternative splicing of ARGLU1.  Furthermore, I 
will show that exogenous overexpression of ARGLU1 leads to dramatic changes in alternative 
splicing of its own endogenous mRNA, causing a decrease in the protein coding isoform, and an 
increase in the retained intron and nonsense mediated decay targeted isoforms.  Additionally, 
overexpression of ARGLU1 causes changes in mRNA levels and alternative splicing in a number 
of genes.  Taken together, these results indicate that ARGLU1 can regulate its own splicing to 
regulate cellular protein levels.  Furthermore, these results suggest that ARGLU1 plays a role in 
cellular alternative splicing. 
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Chapter 1 
Introduction 
1.1 ARGLU1  
This paper will focus on the regulation of a protein called Arginine and Glutamate rich 
protein 1, hereafter referred to as ARGLU1.  The function of ARGLU1 has been poorly described, 
but a number of factors indicate that it is of biological importance.  First, it has been shown that 
depletion of ARGLU1 protein leads to defects in cellular responsiveness to exogenous stimuli such 
as estrogen (Zhang et al., 2011).  Second, ARGLU1 protein sequence is well conserved through 
evolutionary time, indicating a conserved function (Figure 1.1).  In addition to this conservation, 
ARGLU1 also has a region of extraordinarily high non-coding DNA sequence conservation, 
suggesting a consistent selective pressure not only at the level of amino acid sequence (Dimitrieva 
and Bucher, 2013).  Such highly conserved elements have been shown to have a variety of 
important regulatory effects, including transcriptional enhancer activity and regulation of 
alternative splicing, which will be discussed below. 
ARGLU1 is encoded by a gene located at human chromosome 13q33.3.  Initial reports 
involving ARGLU1, which was previously annotated as FLJ10154, focused on rare deletions of 
the 13q33-34 region that overlap ARGLU1 and are associated with microcephaly, developmental 
delay, and genitourinary malformations in males (Andresen et al., 2010; Ballarati et al., 2007; 
Brown et al., 1993, 1995; Quélin et al., 2009; Walczak-Sztulpa et al., 2008).  While the adjacent 
gene EFNB2 was posited to be the gene responsible for these malformations, ARGLU1 is also 
deleted in all reports of genitourinary malformations associated with deletions from this region.   
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Figure 1.1 ARGLU1 Protein Conservation. Multiple-alignment view of ARGLU1 proteins from 
a variety of species, including the frog Xenopus laevis.  Serine residues are highlighted in red, 
arginine residues in green, and glutamate residues in yellow.  Note the enrichment of RS dipeptides 
in the N-terminal region, and the enrichment of glutamate in the c-terminal portion of the protein. 
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A 2009 study investigating glomerulus specific gene expression in the human kidney 
indicated that ARGLU1 was expressed exclusively in the glomerulus, but not in the cortex or 
medulla, of the kidney (Cuellar et al., 2009).  This study used an RT-PCR based assay to 
demonstrate this exclusive expression.  Interestingly, this study used primers that amplify an 
alternatively spliced form of the ARGLU1 transcript that retains an intron between exons 2-3 
(Cuellar et al., 2009), which will be the focus of much of this dissertation.  Therefore, this report 
would seem to indicate that the intron retained isoform is expressed in a very tissue specific 
manner.  Other reports have also indicated that the retained intron isoform of ARGLU1 is 
alternatively spliced in a tissue dependent manner (Braunschweig et al., 2014). 
The most in depth investigation of the function of ARGLU1 protein was made by Zhang 
et al. in 2011.  This study sought to find novel protein interactions with the Mediator complex 
protein MED1 (Zhang et al., 2011).  This study identified ARGLU1 as a MED1 interacting protein 
through affinity purification of MED1 from MCF7 cells, an estrogen receptor positive breast 
cancer cell line, followed by mass spectrometry (Zhang et al., 2011).  They further characterized 
the protein, finding that it was nuclearly localized, and directly interacts with the C-terminus of 
MED1 through its N-terminal arginine-rich domain (Zhang et al., 2011).  Interestingly, a different 
report analyzing the subcellular localization of proteins throughout the cell cycle demonstrated 
that ARGLU1’s nuclear localization was highly dependent on cell cycle stage, peaking in mid-S-
phase, and with the lowest nuclear localization during the G1 phase (Sigal et al., 2006).  As Zhang 
et al. were interested in new regulators of MED1’s role in transcriptional licensing in response to 
estrogen, they showed that ARGLU1 was preferentially co-recruited with MED1 to the promoter 
of the estrogen responsive genes MYC and pS2, but not the control gene GAPDH, following 
estradiol (E2) treatment (Zhang et al., 2011).  They further found that shRNA mediated knock 
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down of ARGLU1 or MED1 decreased expression of these E2 responsive genes, but not GAPDH.  
Finally, they showed that shRNA-mediated knockdown of ARGU1 mRNA  and protein caused 
decreased basal and E2 responsive cellular proliferation and anchorage independent colony 
formation (Zhang et al., 2011).  Taken together, this study indicates that ARGLU1 interacts 
specifically with the MED1 component of the mediator complex, and functions to regulate the 
expression of at least two important estrogen responsive proto-oncogenes. 
1.2 Mediator Complex 
Mediator is a large, multi-subunit complex that is involved in licensing of RNA polymerase 
II in transcription.  Its co-activator function is mediating the interaction of enhancer-bound 
transcription factors and activators, which may be bound to distal enhancer regions, with the core 
RNA pol II pre-initiation complex located at the core gene promoter region (Poss et al., 2013).  
Models of the interaction between the mediator complex and RNA pol II indicate multiple points 
of interaction, but perhaps the most interesting is the interaction with the carboxy-terminal domain 
of RPB1, the largest subunit RNA pol II, which is composed of 52 heptad repeats that are 
extensively and dynamically modified during the transcription cycle (Bentley, 2014).  This subunit 
of RNA pol II serves as a hub for transient interactions of many proteins, including mediator, 
splicing factors, histone modifiers.  It serves as a way to functionally link these factors involved 
in transcription (Bentley, 2014).  Indeed, the MED23 subunit of mediator was recently found to 
interact with a number of proteins involved in mRNA splicing and maturation (Huang et al., 2012).  
This study focused on the interaction between MED23 and hnRNPL, a gene involved in mRNA 
splicing and stability, and found that in the absence of MED23 splicing of a subset of hnRNPL-
regulated genes was altered (Huang et al., 2012).  This mediator-splicing factor interaction, 
possibly potentiated by the CTD of RNA pol II, may serve as a model the interplay between 
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transcriptional activators and splicing regulation.  Given ARGLU1’s interaction with mediator and 
findings, discussed later, that ARGLU1 is involved in alternative splicing, this type of interaction 
will be of future interest. 
1.3 Ultraconserved Elements 
Advances in sequencing technology over the last two decades have laid the foundations for 
a number of advances in our understanding of genome biology (Lander et al., 2001; Venter et al., 
2001) including comparative genomic studies that have furthered our understanding of evolution 
at the nucleotide level (Waterston et al., 2002).  One of the goals of comparative genomics is to 
use evolutionary selection as a marker of biological function (Alföldi and Lindblad-Toh, 2013). 
An important initial study comparing the human genome with that of mice and rats revealed 
hundreds of ultra-conserved elements (UCEs) that they defined as longer than 200 bases of 100% 
sequence identity (Bejerano et al., 2004).  Subsequent analysis found that a set of similarly highly 
conserved non-coding elements functioned as enhancers associated with development (Woolfe et 
al., 2005), or clustered near developmentally regulated genes (Lindblad-Toh et al., 2005), 
indicating that such conservation can indicate regulatory sequences. Further studies have taken a 
slightly different approach, looking for ultra-conserved non-coding sequences over longer 
evolutionary time scales; for example sequences that are more than 95% identical and over 200 
bases between human and chicken (Dimitrieva and Bucher, 2013).  My work has used this standard 
of over 95% conserved nucleotide identity over more than 200 bases between human and chicken 
to define a UCE. 
While one set of highly conserved sequence seems to function in the context of 
transcriptional regulatory regions, another subset of UCEs are postulated to have an RNA 
regulatory function.  One method of analysis of conserved function is to use computational 
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predictions of RNA folding.  Indeed, reports using computational folding predictions based on 
highly conserved non-CDS regions are able to predict transcribed non-coding RNAs (ncRNA) 
with fairly high confidence (Washietl et al., 2005).  Another report by the same group was able to 
identify ncRNA structural conservation even without filtering based on sequence conservation, 
albeit with roughly twice the false positive rate for truly transcribed ncRNAs when compared with 
conservation based prediction methods (Washietl et al., 2007).  Other studies have found that 
sequence conservation is not always a predictor for conserved ncRNA function, good examples 
being certain miRNAs, Xist, Air, and H19, which have known and conserved functions but poor 
sequence conservation (Bentwich et al., 2005; Pang et al., 2006).  So while a high degree of 
conservation may predict ncRNA structure and function in some cases, it is not the only predictor. 
Another RNA function for non-coding UCEs may be in RNA splicing, processing and 
localization.  In this context, these highly conserved sequences would be predicted to serve as 
RNA cis-elements which would interact with trans-elements, namely proteins and protein 
complexes.  A notable example of this is the β-actin mRNA, which is localized to the dendrites of 
hippocampal neurons (Tiruchinapalli et al., 2003) or other subcellular localizations by an 
interaction between a 3’ UTR cis-element called zipcode and the RNA recognition motif (RRM) 
and hnRNP K homology (KH) domains of zipcode binding protein 1 (Farina, 2002; Ross et al., 
1997).  However, these types of cis/trans interactions are usually on the order of tens of bases.  
Indeed the zipcode sequence itself is 54 bases long (Kislauskis et al., 1994), whereas 
ultraconserved elements require at least 200 bases of conservation.  One could thus hypothesize 
that such long cis-elements may be concatenations of binding sites for multiple trans-factors, or 
that they coordinate multiple types of regulation, such as splicing, sub-cellular localization, 
nuclear-cytoplasmic trafficking and translation.   
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Indeed, highly- and ultra-conserved sequences have been associated with conserved and 
tissue specific alternative splicing events (Baek and Green, 2005; Lareau et al., 2007; Ni et al., 
2007; Sugnet et al., 2006).  Of particular interest are the association between highly conserved 
sequences and alternative splicing of many SR and hnRNP proteins, which are themselves 
regulators of splicing (Lareau et al., 2007; Ni et al., 2007).  It is now well established that these 
alternative splicing events are linked with a cellular quality control mechanism known as nonsense 
mediated decay (NMD) (Baek and Green, 2005; Lareau et al., 2007; Lewis et al., 2003; Ni et al., 
2007); however another recent study has linked UCE-related intron retention alternative splicing 
to a different regulator mechanism that they labeled ‘detained introns’ (Boutz et al., 2015).  While 
I want to highlight this association between highly conserved sequences and alternative splicing, 
I will further discuss the critical splicing-associated proteins regulated by these elements, their 
roles in splicing, as well as the mechanisms and outcomes of their alternative splicing in a later 
section. 
1.4 RNA splicing—Coordination of spliceosome assembly by cis- and trans-acting factors 
RNA splicing is a process by which exon sequences from a primary RNA transcript are 
brought together, and the intervening introns are removed. This process was first appreciated in 
adenovirus (Berget et al., 1977; Chow et al., 1977).  Sharp and colleagues observed R-looping of 
DNA following hybridization of polyribosome-associated viral RNA to viral DNA treated with 
restriction enzymes, and proposed that this was the result of bringing together and joining specific 
sequences within large, nuclear viral transcripts (Berget et al., 1977).  In a report published just a 
month later, Richard Roberts and colleagues reported similar results mapping R-loop interactions, 
and concluding that these sequences were not coded linearly by the DNA genome of the virus 
(Chow et al., 1977).  The report by the Sharp group (Berget et al., 1977), and a separate report by 
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Daniel Klessig (Klessig, 1977), proposed a model that is in line with our current understanding of 
RNA splicing, whereby the 3’-end of one segment is brought together with the 5’-end of the next 
segment and the intervening sequences are looped out and removed.  Shortly thereafter, a number 
of groups reported splicing of a wide variety of metazoan genes, including the rabbit (Jeffreys and 
Flavell, 1977) and mouse (Tilghman et al., 1978) β-globin genes, the chicken ovalbumin gene 
(Breathnach et al., 1977), and the immunoglobulin light chain (Tonegawa et al., 1978).  
Development of a method to splice RNA molecules in vitro (Grabowski et al., 1984; Kole 
and Weissman, 1982; Krainer et al., 1984; Padgett et al., 1983; Ruskin et al., 1984) allowed for 
further dissection and identification of the component sequences of a splicing reaction, namely the 
5’-splice site and 3’-splice site (Mount, 1982), and branch point (Konarska et al., 1985).  The 
splicing reaction came to be understood to be two sequential transesterification reactions.  In the 
first step, the 5’-splice site, with a consensus sequence of MAG|GURAGU where M is A/C and R 
is A/G, is brought into contact with the branch point, an AU upstream of the 3’-splice site, and the 
5’ G of the GU dinucleotide is joined by a 2’-5’ phosphodiester linkage to adenosine of the branch 
point (Konarska et al., 1985), forming a structure known as a lariat (Padgett et al., 1984).  In the 
second step of splicing, the 3’-splice site, which has a consensus YAG|G, where Y is a pyrimidine, 
is cleaved following the AG, and the 5’-end of the 3’ exon is joined to the 3’-end of the of the 
upstream exon by a 3’-5’ phosphodiester bond (Grabowski et al., 1984). 
During this same time, it was recognized that snRNP complexes, composed of small 
nuclear RNAs (snRNAs), as well as protein components interact with specific sequences on the 
RNA (Chabot et al., 1985) and function to mediate the splicing reaction by dynamically bringing 
together the mRNA components of the splicing reaction.  These snRNP complexes were first 
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identified using anti-nuclear antibodies produced by patients with Systemic Lupus Erythematosus 
(Lerner and Steitz, 1979). 
This dynamic macromolecular complex, called the spliceosome, is characterized by the 
formation of a number of distinct complexes that coordinate the two transesterification reactions 
of RNA splicing.  The first complex formed, complex E, begins with U1 snRNP binding through 
U1 mediated base pairing to the 5’-splice site. Additionally during complex E formation, a protein 
called splicing factor 1 (SF1) or branch point binding protein (BPB) is recruited to the branchpoint, 
and the subunits of the U2 auxiliary factor A2, U2AF65 and U2AF35 (Zamore et al., 1992), bind 
to the polypyrimidine tract and the characteristic 3’splice site AG, respectively (Wahl et al., 2009).  
Prior to and during this stage proteins, including the SR and hnRNP families, are recruited to the 
RNAs through cis-elements and can promote or repress binding of these complex E factors.  These 
regulatory proteins will be discussed in greater detail in later sections.  Complex A is then formed, 
with the displacement of SF1/BPB by the U2 snRNP at the branch point (Wahl et al., 2009).  Next, 
complex B is formed by the recruitment of the U4/U5/U6 tri-snRNP, with U5 base-pairing to the 
5’-splice site (Wahl et al., 2009).  This leads to destabilization of the complex, and the U1 and U4 
snRNPs exit the complex.  At the same time, U6 base pairs with the 5’-splice site, displacing U5.  
With the hydrolysis of ATP, the catalytic spliceosome is generated and catalyzes the first 
transesterification reaction in which the 2’ hydroxyl of the branch point adenosine attacks the 5’ 
phosphate of the 5’-splice site guanidine, forming the lariat.  The complex then rearranges again, 
with U5 binding to the 3’-splice site, bringing the upstream and downstream exons together.  With 
U2/U5/U6 still bound, the free 3’-hydroxyl of the 5’-exon attacks the 5’ phosphate bond of the 3’-
ss, and the ligation reaction is carried out following ATP hydrolysis. (Will and Lührmann, 2011).  
This process is well reviewed elsewhere (Wahl et al., 2009; Will and Lührmann, 2011). 
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There is a large body of work that has sought to define the complement of proteins involved 
in the spliceosome.  One productive system has been affinity purification of proteins and RNAs 
associated with different stages of spliceosome assembly followed by mass spectrometry.  
Interestingly, ARGLU1 protein has been found in multiple preparations of spliceosome 
complexes, including complex A (Behzadnia et al., 2007), the active step 1 spliceosome (Bessonov 
et al., 2008), and purified complex B (Deckert et al., 2006).  Based on the finding that ARGLU1 
was associated with the spliceosome, it was included in a yeast 2-hybrid screen for protein-protein 
interactions between spliceosome proteins.  In that experiment, ARGLU1 was found to interact 
with itself, CHERP, PRMT5, SRPK2, and ZCCHC10 (Hegele et al., 2012).  Another high 
throughput protein-protein interaction screen, this time in drosophila, found that the ARGLU1 
homolog CG31712 was associated with spliceosome components, including the U1-70K protein 
and CG4119 (Guruharsha et al., 2011).  A high throughput assay of protein kinase targets identified 
ARGLU1 as a phosphorylation target of both SRPK1 and SRPK2 protein kinases (Varjosalo et al., 
2013).  A list of proteins interacting with ARGLU1 is found in Table 1.1. These interactions are 
especially interesting in the context of our experimental findings, as the SRPK protein kinases are 
known to regulate SR proteins, an important class of splicing regulators that will be covered in a 
later section in more detail.  Taken together, these interactions indicate that ARGLU1 interacts 
with components of the spliceosome.  However, proteomic studies designed to determine the full 
array of RNA binding proteins have not provided evidence that ARGLU1 interacts directly with 
mRNA (Baltz et al., 2012; Castello et al., 2012). 
  
 
 
11 
 
Official 
Symbol 
Interactor 
A 
Official 
Symbol 
Interactor 
B 
Experimental 
System 
Experimental 
System Type 
Author 
Pubmed 
ID 
IKBKG ARGLU1 
Reconstituted 
Complex 
physical Fenner BJ (2010) 20098747 
ELAVL1 ARGLU1 
Affinity Capture-
RNA 
physical 
Abdelmohsen K 
(2009) 
19322201 
SF3A2 ARGLU1 
Affinity Capture-
MS 
physical 
Behzadnia N 
(2007) 
17332742 
CDK2 ARGLU1 
Affinity Capture-
MS 
physical 
Neganova I 
(2011) 
21319273 
ARGLU1 APP 
Reconstituted 
Complex 
physical Olah J (2011) 21832049 
CHERP ARGLU1 Two-hybrid physical Hegele A (2012) 22365833 
ARGLU1 CHERP Two-hybrid physical Hegele A (2012) 22365833 
ARGLU1 ARGLU1 Two-hybrid physical Hegele A (2012) 22365833 
ARGLU1 PRMT5 Two-hybrid physical Hegele A (2012) 22365833 
ARGLU1 ZCCHC10 Two-hybrid physical Hegele A (2012) 22365833 
ARGLU1 SRPK2 Two-hybrid physical Hegele A (2012) 22365833 
PRMT5 ARGLU1 Two-hybrid physical Hegele A (2012) 22365833 
ZCCHC10 ARGLU1 Two-hybrid physical Hegele A (2012) 22365833 
SRPK2 ARGLU1 Two-hybrid physical Hegele A (2012) 22365833 
SRPK2 ARGLU1 
Biochemical 
Activity 
physical 
Varjosalo M 
(2013) 
23602568 
SRPK1 ARGLU1 
Biochemical 
Activity 
physical 
Varjosalo M 
(2013) 
23602568 
CUL7 ARGLU1 
Affinity Capture-
MS 
physical Hanson D (2014) 24711643 
EED ARGLU1 
Affinity Capture-
MS 
physical Cao Q (2014) 24457600 
Table 1.1 Known Protein-Protein interactions for ARGLU1 
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1.5 Intron and Exon Definition 
There are two models for how initial assembly of the spliceosome components occurs: 
intron definition and exon definition.  The intron definition model posits that components of the 
spliceosome assemble and interact across small introns (Talerico and Berget, 1994), where the 5’ 
and 3’ splice sites are close to each other in space.   In vitro and transfection splicing assays have 
shown that as intron length rises above 250 nucleotides, splicing becomes quite inefficient (Fox-
Walsh et al., 2005).  This same study found that increased inclusion of human alternatively spliced 
exons was associated strongly with a shorter upstream intron (Fox-Walsh et al., 2005).  
Furthermore, this study found that inclusion of an RNA cis-element known as an exonic splice 
enhancer (ESE) could dramatically increase splicing efficiency of even longer introns (Fox-Walsh 
et al., 2005).  While intron definition mediated splicing seems to be the exception rather than the 
rule in mammals, it is seen almost exclusively in plants, fungi and invertebrates (Talerico and 
Berget, 1994; Xiao et al., 2007).  Consequently, vertebrates have developed a complex set of 
regulatory elements to enforce the correct usage of exons within the context of long introns that 
often contain pseudoexons with paired 3’- and 5’-splice sites (Xiao et al., 2007).  These elements 
will be discussed further below. 
The second model for assembling spliceosome components is called exon definition, and 
occurs by the assembly of snRNP complexes to either end of an exon (Robberson et al., 1990; 
Sterner et al., 1996).  These assembled mRNA/snRNP complexes can then form associations 
across introns mediated by interactions between snRNPs and other splicing associated proteins.  
The exon definition model is supported by evidence that U1 snRNP binding to the 5’ss of an exon 
stimulated splicing of the upstream 5’ss to the 3’ss of that exon (Kuo et al., 1991).  It was found 
that polypyrimidine tracts play an important role in potentiating the exon definition model by 
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recruiting important protein factors such as U2AF (Dominski and Kole, 1992; Talerico and Berget, 
1994). Similar to the intron definition model, there appears to be a size limit to the exon definition 
model, with failure of exon definition by in vitro splicing inclusion of exons larger than 
approximately 300 bases (Robberson et al., 1990), while exons larger than approximately 500 
bases are poorly included in transfection splicing studies, especially in the context of long introns 
(Sterner et al., 1996).  Thus, there seem to be limits on the size of either exons or introns for their 
definition in splicing. 
Early studies indicated that there is also a lower size limit for exon definition of 
approximately 50 nt (Dominski and Kole, 1991), although inclusion of small exons could be 
modulated by altering the splice site strength or upstream polypyrimidine tract and branch point 
(Dominski and Kole, 1991, 1992).  The use of high throughput RNA sequencing techniques has 
allowed for the identification of a large number of 3-27 nt small exons, which they have termed 
microexons, which are used in neurons and are misregulated in the autistic brain (Irimia et al., 
2014).  Interestingly, there have been a number of groups that have identified zero length exons, 
which function in the splicing of exceptionally long exons in drosophila (Burnette, 2005; Duff et 
al., 2015; Hatton et al., 1998) and humans (Duff et al., 2015; Sibley et al., 2015) through a process 
called recursive splicing where the removal of an intron regenerates a 5’ss that can be used for 
further splicing.  These types of events have challenged the classical concept of an exon, as they 
are simply the juxtaposition of a 3’ and 5’-splice site. 
1.6 Alternative splicing 
One of the earliest reported examples of RNA splicing was the human immunoglobulin 
light chain (Tonegawa et al., 1978).  Soon after this discovery, the immunoglobulin gene played 
an important role in understanding how RNA splicing lead to the incredible diversity of molecules 
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derived from this locus (Alt et al., 1980; Early et al., 1980) through a process known as alternative 
splicing (AS), whereby a precursor RNA (pre-mRNA) transcript can be processed to include or 
exclude exons in the final mature mRNA.  Alternative splicing plays a number of important roles 
in cells, including expanding the protein repertoire of cells (Nilsen and Graveley, 2010), allowing 
temporal and tissue specific control of protein expression (Wang et al., 2008), and response to 
cellular stimuli (Braunschweig et al., 2013).  AS seems to be an important and widely used 
mechanism, as recent studies have concluded that approximately 95% of all genes in the human 
genome generate more than one spliced isoform (Pan et al., 2008; Wang et al., 2008).  
Technological advances in the past two decades such as microarray and more recently RNA-Seq 
technologies have allowed for mapping and quantitation of an ever increasing number of 
alternatively spliced RNAs across a host of species. 
There are a number of common types of alternative splicing (Fig 1.2).  Most common is 
the cassette exon, which is a simple inclusion/exclusion event.  Other types include alternative 5’-
splice site, alternative 3’-splice site, mutually exclusive exon usage, and intron retention.  More 
complex sets of alternative splicing can be created by combining these types of alternative events.  
An example relevant to our study is the combination of an intron retention event and a cassette 
exon with alternative 5’-splice sites on the cassette exon.  It is easy to see how this can rapidly 
increase the number of isoforms derived from one pre-mRNA. 
Alternative splicing is regulated by the interactions between cis-elements within RNA 
molecules and trans-acting proteins that bind to these RNA sequences.  We will discuss the details 
of these regulatory elements below.   
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Figure 1.2 Types of alternative splicing.  The various types of alternative splicing are depicted 
in cartoon form.  Constitutive exons are colored blue, while alternative exon are colored to 
differentiate them. 
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1.7 Cis-elements regulating splicing 
The exon definition process, discussed earlier, is modulated through the interaction of cis-
acting RNA elements with trans-acting proteins, such as SR or hnRNP proteins (Caceres et al., 
1994).  The cis-elements that inform exon definition, generally known as Splicing Regulatory 
Elements (SREs), can be defined as exonic splice enhancers of suppressors (ESEs or ESSs) or 
intronic splice enhancers or silencers (ISEs or ISSs), based on their location and propensity to 
promote or suppress inclusion of the associated exon (Wang and Burge, 2008).  The 5’- and 3’- 
consensus splice sites are only 9 bases and 4 bases, respectively, and thus found quite frequently 
in the genome.  Furthermore, the introns separating these sequences are often hundreds or 
thousands of bases long, making these cis-elements critical for more specificity in the recruitment 
of the core spliceosomal components (Wang and Burge, 2008).   
Many studies have defined cis-elements using a variety of techniques. Classic studies 
identified individual cis-elements through molecular biology techniques such as mutagenesis and 
deletion of specific sequences proximal to regulated exons within minigene reporters (Schaal and 
Maniatis, 1999; Sun and Chasin, 2000).  Other SREs have been deduced from pathogenic SNPs 
linked to modification of splicing, notably in the CFTR gene (Pagani et al., 2003), and the SMN2 
gene (Cartegni and Krainer, 2002).  However, high throughput screens and computational 
approaches have led to more general identification of SREs.  For example, cloning of random 
sequences into the middle exon of multi-exon reporters followed by selection for inclusion of that 
exon has been used to identify ESE sequences in both in vitro (Tian and Kole, 1995) and in vivo 
splicing assays (Coulter et al., 1997), both of enriched for purine-rich sequences, similar to analysis 
of individual ESEs that had been found to interact with SR proteins (Dirksen et al., 1994; 
Lavigueur et al., 1993; Lynch and Maniatis, 1995; Tanaka et al., 1994).  Another useful high 
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throughput approach has been to split green fluorescent protein with an internal exon that disrupts 
its fluorescence.  The inclusion or exclusion of this internal exon can be modulated by insertion of 
random sequences within either the exon or in adjacent introns.  This system was first used to 
screen random decamers for their ability to cause skipping of the internal exon and thus green 
fluorescence, indicating their ability to function as ESSs (Wang et al., 2004).  More recently, this 
same group has used a similar approach to screen both ISSs (Wang et al., 2013) and ISEs (Wang 
et al., 2012).  The information gained from such high-throughput screens can then be applied to 
predict splicing regulation of other exons. 
1.8 Trans-acting Splicing Regulators 
These cis-elements act through interactions with trans-acting proteins that serve to promote 
or inhibit spliceosome subunit binding, based on the RNA element and the protein recruited (Wang 
and Burge, 2008).  These trans-acting proteins mostly fall into two large classes of proteins, 
although there are other splicing regulatory proteins that do not easily fit into either class (Fu and 
Ares, 2014).  Early studies showed that stereotypical proteins within these two families of proteins, 
SR proteins and hnRNP proteins, had generally antagonistic effects on the inclusion of 
alternatively spliced exons (Caceres et al., 1994; Mayeda and Krainer, 1992; Mayeda et al., 1994), 
although more recent studies have indicated a more nuanced effect of these proteins on exon 
inclusion/exclusion (Huelga et al., 2012; Pandit et al., 2013). 
The first class of trans-acting regulators are the hnRNP proteins, which are generally held 
to have an inhibitory role in exon inclusion.  The most well studied hnRNP proteins have been 
shown to have splicing inhibitory roles, and include hnRNPA/B family (Mayeda and Krainer, 
1992; Mayeda et al., 1994; Yang et al., 1994) as well as polypyrimidine tract-binding protein 
(PTB) (Singh et al., 1995).  The mechanism by which these proteins cause inhibition of exon 
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inclusion is still unclear, although recent studies have begun to explain their effects.  Studies have 
proposed that hnRNP A/B initially bind to ISS or ESS sequences and subsequently oligomerize to 
cover nearby RNA sequences, thereby preventing binding of SR proteins that promote splicing 
(Okunola and Krainer, 2009; Zhu et al., 2001).  A recent study sought to understand the genes 
regulated by a variety hnRNP proteins in human cells.  They used both siRNA mediate knockdown 
to identify alternative splicing events regulated by these proteins, as well as a technique known as 
CLIP-seq to map the interactions between the hnRNP proteins and their target RNAs, which 
revealed  (Huelga et al., 2012).  This study produced a number of interesting results, including the 
fact that knockdown of hnRNP proteins caused the increased or decreased inclusion of a large 
number of cassette exons, indicating that hnRNP proteins are not exclusively inhibitory, but play 
a more complicated role in balancing the usage of certain exons.  Furthermore, they presented 
evidence for hnRNPs cross-regulating other RNA binding proteins, including other hnRNPs and 
SR proteins (Huelga et al., 2012). 
PTB is another RNA binding protein generally thought to be inhibitory to exon inclusion 
which has been shown to interact with intronic polypyrimidine tracts upstream of 3’-splice sites 
(Singh et al., 1995) and is proposed to block cross-intron interactions between the 5’- and 3’-splice 
sites after assembly of the A complex and exon definition (Sharma et al., 2005, 2008).  
Additionally, PTB has been shown to interact directly with U1 at the 5’ss and stabilizing the 
interaction (Sharma et al., 2011).  This particular study may be of further interest, as it suggests a 
mechanism for inhibiting splicing of upstream and downstream exons over long distances, by 
locking them in a conformation that does not allow progression beyond the spliceosomal E 
complex, thus stalling the splicing reaction (Roca et al., 2013).  Deletion of the mouse homolog of 
PTB, Ptbp1, was shown to regulate a number of neuron specific intron retention events, causing 
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the nuclear retention of these transcripts (Yap et al., 2012).  Other studies have shown that binding 
of SR protein SRSF7 to intronic regions downstream of exons will inhibit their splicing by 
preventing progression beyond the spliceosomal E complex, while still allowing recruitment of U1 
to the 5’-splice site (Erkelenz et al., 2013), perhaps suggesting a similar role to PTB.  The role of 
hnRNPs seems to be complicated, and may range from negatively modulating the recruitment of 
spliceosome components through competition with SR proteins to inhibiting the rearrangement of 
these components into a committed complex. 
The second large family of splicing regulatory proteins are known as SR proteins (for 
serine/arginine-rich proteins).  SR proteins take their name as the result of a characteristic C-
terminal RS domain, which is enriched in clustered Serine-Arginine dipeptides.  Furthermore, 
these proteins have one or two N-terminal RNA-recognition motifs (RRMs), similar to many other 
RNA binding proteins including hnRNP proteins (Bandziulis et al., 1989; Zahler et al., 1992).  
These proteins are known to localize to subnuclear bodies known as splicing speckles, which are 
repositories for splicing factors (Spector et al., 1991).  Furthermore, the function and localization 
of SR proteins is regulated by the phosphorylation state of their RS domains (Cáceres et al., 1997), 
which is dependent on multiple protein kinases, including SRPK1 (Gui et al., 1994), SRPK2 
(Wang et al., 1998), and the CLK kinases (Colwill et al., 1996), as well as long non-coding RNAs 
such as MALAT1 (Tripathi et al., 2010).   
The presence and function of the SR family of proteins was first recognized in the 
Drosophila development system, where a cascade protein factors regulate sex determination 
through auto-regulatory splicing as well as alternative splicing of the downstream transcripts 
(Amrein et al., 1988, 1994; Bell et al., 1988; Boggs et al., 1987; Goralski et al., 1989).  Shortly 
thereafter, a number of human proteins were found that shared protein sequence and functional 
 
 
20 
 
similarities to the splicing regulators found in Drosophila, such as ASF/SF2 (Ge and Manley, 
1990; Ge et al., 1991; Krainer et al., 1991; Mayeda and Krainer, 1992), now known as SRSF1, and  
SC-35 (Fu and Maniatis, 1992a), now known as SRSF2.  It was recognized that these SR proteins 
interact with cis-elements, the SREs discussed earlier, to carry out their regulatory role (Dirksen 
et al., 1994; Sun et al., 1993).  SR proteins have been shown to interact with each other, as well as 
other RS domain containing proteins such as the U1 snRNP (Wu and Maniatis, 1993).  
Furthermore, SR proteins seems to have overlapping ability to interact with other proteins to 
potentiate splicing, as they can functionally complement each other (Fu et al., 1992).  Additionally, 
SR proteins can interact with U1 snRNP and U2AF proteins to recruit them to the 5’ (Kohtz et al., 
1994; Wu and Maniatis, 1993) and 3’-splice site (Fu and Maniatis, 1992b), respectively, and 
promote exon definition as discussed earlier.  Interestingly, the RS domains of SR proteins can 
still function to potentiate splicing independent of the RRM domain, when tethered to pre-mRNAs  
(Graveley and Maniatis, 1998; Graveley et al., 1998).  Thus, a general model of SR proteins has 
their RRMs mediating RNA binding specificity, while their RS domains allow for protein-protein 
interactions important for exon definition and spliceosome assembly. 
Other proteins involved in regulation of splicing are expressed in tissue specific patterns, 
allowing for activation of alternative splicing programs important for cellular specialization.  Most 
notably, trans-acting proteins such as the NOVA (Licatalosi et al., 2008; Ule et al., 2003; Yano et 
al., 2010; Zhang et al., 2010), and RBFOX (Li et al., 2014; Weyn-Vanhentenryck et al., 2014; Yeo 
et al., 2009) protein families, and  tissue specific SR proteins such as nSR100 (Calarco et al., 2009; 
Irimia et al., 2014) compete to bind nascent RNAs at specific motifs and drive regulation of 
alternative splicing in a tissue and developmentally regulated manner.   
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Several recent studies have employed a variety of techniques to identify splicing events 
regulated by SR proteins.  The use of high throughput techniques such as RNA splicing-specific 
microarrays and RNA-seq experiments have helped to understand the subset of splicing events 
regulated by specific SR proteins.  Furthermore, techniques such as CLIP-seq have allowed for 
high throughput identification of RNAs bound by these proteins.  For example, the cellular RNAs 
bound by SRSF1 were mapped using CLIP-Seq, which revealed that this protein interacts with 
predominantly mRNAs at the exon-intron border, but also binds a variety of  other cellular RNAs, 
including  lncRNas and intronless genes (Sanford et al., 2009).   Another example of CLIP-seq 
being used to understand the regulatory landscape of SR proteins is the mapping binding sites of 
SRSF3 and SRSF4 (Ankö et al., 2010; Änkö et al., 2012), which showed that these two SR proteins 
bind distinct subsets of RNA, and preferentially regulate different types of splicing events. 
1.9 NMD and splicing 
One role of alternative splicing seems to be the regulation of transcript abundance through 
cellular RNA decay pathways, notably the Nonsense-Mediated Decay (NMD) pathway.  NMD is 
a cellular quality control pathway that degrades RNA transcripts that contain premature 
termination codons (PTCs), which if translated result in truncated proteins.  The ability of PTCs 
to cause RNA stability was first recognized in yeast (Losson and Lacroute, 1979).  Subsequently, 
it was recognized that patients with thalassemia resulting from frame shifting mutations leading to 
PTCs caused rapid turnover of RNA, but this turnover could be repressed with the translational 
inhibitor actinomycin D (Kinniburgh et al., 1982; Maquat et al., 1981).  PTCs may arise from a 
number of sources, including DNA mutations, inaccurate transcription leading to frameshifts or 
single nucleotide nonsense mutations, or from alternative splicing that puts stop codons in frame 
in an inappropriate position.   
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One of the key factors in NMD is a multi-subunit complex known as the Exon Junction 
Complex (EJC), which, as its name implies, marks the junction between two exons resulting from 
splicing.  The EJC is deposited upstream of splicing junctions in a sequence-nonspecific manner 
mainly through the interaction between the spliced RNAs and eIF4AIII (Shibuya et al., 2004), a 
DExH/D RNA helicase which is deposited during the second step of RNA splicing (Zhang and 
Krainer, 2007) and acts as a scaffold for the further association of other proteins such as Magoh 
and Y14.  The EJC is important for a number of cellular processes, such as nuclear export and 
subcellular localization (Schell et al., 2002) as well as translation (Nott et al., 2003, 2004; Wiegand 
et al., 2003).  Most importantly for this discussion, however, it acts as an important scaffold for 
the NMD machinery, as the critical NMD factors UPF3 is added during splicing, and is joined by 
UPF2 in the cytoplasm (Chamieh et al., 2008; Le Hir et al., 2001; Kervestin and Jacobson, 2012). 
During the pioneer round of translation of a transcript with a PTC, the ribosome will cause 
a change in the protein composition of the mRNP, displacing the compliment of proteins that 
accompanied the mRNA out of the nucleus, including the EJC (Ishigaki et al., 2001; Lejeune et 
al., 2002).  If the ribosome recognizes a stop codon during translation, it recruits release factors, 
such as eRF1 and eRF3, which are associated with the NMD-associated protein UPF1.  If the stop 
codon is more than ~50 nt upstream of the EJC (i.e., a PTC), a stable interaction will take place 
between UPF1 and UPF2, bridging UPF1 with the EJC.  This in turn leads to phosphorylation of 
UPF1 and recruitment of either SMG6, an endonuclease that cleaves the NMD targeted RNA, or 
the SMG5-SMG7 complex that is associated with uncapping and deadenylation of RNAs.  Either 
of these pathways leads to rapid degradation of the targeted RNA. 
As mentioned previously, NMD is coupled to splicing in a number of ways.  First, it is the 
act of splicing that deposits the EJC on mRNAs.  However, another important link may be that 
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alternative splicing can lead to the regulated inclusion of PTCs that lead to preferential degradation 
of certain gene transcripts over others.  This may represent a method of regulation that is dependent 
on alternative splicing rather than transcriptional regulation.  Interestingly, this mechanism seems 
to be especially common in the regulation of splicing factors including SR proteins and hnRNP 
proteins (Lareau et al., 2007; Ni et al., 2007; Saltzman et al., 2008). 
This link between NMD and alternative splicing was first appreciated in a genome wide 
manner when a comprehensive study of expressed sequence tags (ESTs) found that a number of 
alternatively spliced genes were found to have isoforms that would be predicted to be subject to 
NMD (Lewis et al., 2003).  These authors termed this phenomenon regulated unproductive splicing 
and translations (RUST).  They extended this line of inquiry further, and showed that any of these 
alternative splicing events were also conserved between human and mouse (Baek and Green, 
2005), and that AS of these predicted NMD targets was linked with the presence of ultra- or highly-
conserved elements at the sites of alternative splicing, especially in SR and hnRNP proteins 
(Lareau et al., 2007; Ni et al., 2007).  Further detailed experimental evidence also showed that 
specific SR proteins, including SRSF1 (Sun et al., 2010) and SRSF2 (Sureau et al., 2001), 
produced NMD-sensitive splice isoforms that were modulated by overexpression of the protein 
coding transcripts.  Taken together, these data indicate that there is a conserved regulatory system 
of splicing factors that takes advantage of NMD to post-transcriptionally modulate protein levels. 
1.10 Retained and Detained introns  
Intron retention is a specific type of alternative splicing that has been poorly studied until 
recently.  It is characterized by the lack of removal of an intron in an otherwise processed 
transcript.  Retained introns can shape the fate of RNAs in a number of ways, including inhibiting 
nuclear export (Nott et al., 2003), causing NMD through the inclusion of an in-frame PTC (Ge and 
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Porse, 2014), as well as altering coding potential (Bell et al., 2008, 2010; Buckley et al., 2011; 
Dirksen et al., 1995).  The regulation of intron retention seems to be complex, with the interactions 
of a number of SREs, and thus necessarily their interacting trans-factors.  However, there are a 
number of important regulatory elements.  Perhaps most obviously, informatics studies have 
indicated that weak 5’ and 3’-splice sites are correlated with intron retention (Sakabe and de Souza, 
2007).  It has also been recognized that multiple 5’ss-like sequences (i.e., complementarity to U1) 
in close proximity can compete with each other (Pagani et al., 2002; Siebel et al., 1992).  
Furthermore, a number of ESS sequences identified in high throughput screens have been 
associated with increased intron retention (Wang et al., 2004).  One of the most important trans-
factors important for intron retention is PTB, which has been shown in a number of studies to be 
associated with intron retention, both by in vitro experiments (Marinescu et al., 2007; Sharma et 
al., 2005, 2008, 2011), and in the effect of animal knock out models (Yap et al., 2012). 
This form of alternative splicing was thought to be less common than other types in 
mammals (Galante et al., 2004; Michael et al., 2005), and more common in single celled 
eukaryotes (Parenteau et al., 2011) and plants (Ner-Gaon et al., 2004), and is critical for many 
viruses (Li et al., 2006).  However, a number of recent studies have revealed that this type of 
alternative splicing is more widespread than initially thought.  First, intron retention has been seen 
in a number of cancers (Dvinge and Bradley, 2015; Simon et al., 2014; Sowalsky et al., 2015; 
Zhang et al., 2014).  There have been a number of proposed mechanisms for this increased intron 
retention, including global increases in transcription levels leading to saturation of the splicing 
machinery (Sowalsky et al., 2015) or changes in histone methylation as the result of SETD2 
mutation (Simon et al., 2014).  However, intron retention seems to play other, more regulated roles 
as well.  For example, recent studies have shown that intron retention is regulated in a tissue 
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specific and developmentally regulated manner (Braunschweig et al., 2014).  T cells demonstrate 
intron retention in a specific set of genes that is regulated by hnRNPLL (Cho et al., 2014).  
Additionally, granulocyte development causes a regulated intron retention in 86 genes linked to 
NMD degradation of those mRNAs (Wong et al., 2013). 
As mentioned previously, transcripts with retained introns often have PTCs that are 
associated with regulation by NMD.  While this seems to be an important mechanism to regulate 
protein levels through alternative splicing, a recent study has demonstrated that a large number of 
polyadenylated transcripts with retained introns localize to the nucleus, are not degraded by NMD, 
and can undergo induced splicing following cellular stress or treatment with an inhibitor of the Clk 
family of kinases (Boutz et al., 2015).  The authors label RNAs with these characteristics “detained 
introns,” and suggest that they may represent a mechanism for storing transcripts for rapid splicing 
and export.  Importantly to the current study, ARGLU1 was identified as a “detained intron” 
transcript in both human and mouse cells. 
1.11 Conclusion 
In this introduction, I have tried to present context for the rest of the dissertation.  To 
summarize, ARGLU1 is a nuclearly localized protein.  ARGLU1 transcripts have been previously 
reported to be alternatively spliced in a number of ways, including the presence of a retained intron.  
ARGLU1 protein interacts with members of the mediator complex as well as the spliceosome.  In 
this dissertation, I will investigate the cis-regulatory landscape of ARGLU1 alternative splicing.  
Furthermore, I will present evidence that ARGLU1 protein can function to homeostatically 
regulate its own level by feeding back and altering splicing of its own transcript. 
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Chapter 2: ARGLU1 Alternative Splicing is Regulated by the Presence of an 
Ultraconserved Element 
2.1 Introduction 
In this chapter I will explore the regulation of alternative splicing of transcripts from the 
gene ARGLU1.  ARGLU1, previously known as FLJ10154, is a gene with a poorly defined cellular 
function.  The most in depth study describes ARGLU1’s interaction with a protein called MED1, 
a component of the mediator complex (Zhang et al., 2011).  The mediator complex functions to 
bring the transcriptionally poised RNA pol II complex into contact with transcription factors, thus 
allowing transcription to proceed.  In their 2011 study, Zhang et al. demonstrated that in the context 
of estrogen receptor (ER) dependent MCF7 cells, ARGLU1 potentiated increased expression of 
the ER responsive genes MYC and pS2, but not the housekeeping gene GAPDH, after treatment 
with estradiol (Zhang et al., 2011).  Furthermore, shRNA-mediated knockdown of ARGLU1 led 
to a decrease in the growth and adhesion-independent survival of MCF7 cells, with and without 
estrogen stimulation (Zhang et al., 2011). 
Interestingly, other reports indicate a possible role for ARGLU1 in a different cellular 
context, namely in RNA splicing.  ARGLU1 protein has been found in multiple preparations of 
spliceosome complexes, including complex A (Behzadnia et al., 2007), the active step 1 
spliceosome (Bessonov et al., 2008), and purified complex B (Deckert et al., 2006).  Additionally, 
ARGLU1 has been found to interact with (Hegele et al., 2012), and be phosphorylated by 
(Varjosalo et al., 2013), multiple members of the SRPK family of protein kinases, which regulate 
a family of proteins important for splicing, known as SR proteins (Aubol et al., 2013; Wang et al., 
1998; Zhong et al., 2009).  Additionally, the Drosophila homolog of ARGLU1, CG31712, has 
been shown to associate with U1-70K (Guruharsha et al., 2011), a key player in the assembly of 
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the spliceosome that has previously been shown to interact with SR and SR-like proteins 
(Blencowe et al., 2000; Fu and Maniatis, 1992b; Park et al., 2004).   
Alternative splicing is a process by which a precursor mRNA (pre-mRNA) can be 
assembled with the inclusion or exclusion of certain exons, leading to multiple mature mRNAs.  
As discussed previously, regulation of alternative splicing is mediated by interactions between cis-
elements within the RNA molecules and trans-acting protein complexes that recognize and bind 
to these cis-elements.  The cis-elements that inform exon definition, generally known as Splicing 
Regulatory Elements (SREs), can be defined as exonic splice enhancers of suppressors (ESEs or 
ESSs) or intronic splice enhancers or silencers (ISEs or ISSs), based on their location and 
propensity to promote or suppress inclusion of the associated exon (Wang and Burge, 2008).  There 
have been a number of techniques used to identify cis-elements regulating splicing.  Studies 
originally identified these sequences through pathogenic mutations in diseases such as cystic 
fibrosis, in the CFTR gene (Pagani et al., 2003), and spinal muscular atrophy, in the SMN2 gene 
(Cartegni and Krainer, 2002).  Other individual cis-elements were discovered through molecular 
biology techniques such as mutagenesis and deletion of specific sequences proximal to regulated 
exons within minigene reporters (Schaal and Maniatis, 1999; Sun and Chasin, 2000). 
The alternative splicing of a number of SR proteins has been correlated with the presence 
of ultra-conserved or highly-conserved elements within the primary transcripts of a number of 
their genes, including SRSF1, SRSF2, SRSF4, SRSF4, SRSF5, SRSF6, SRSF7, SRSF9, SRSF10, 
and SRSF11 (Lareau et al., 2007; Ni et al., 2007) as well as the genes for the hnRNP proteins 
HNRPDL, HNRPH1, HNRPK and HNRPM (Ni et al., 2007).  These studies correlated these highly 
conserved sequences with alternative splicing isoforms that were subject to NMD, as knockdown 
of the core NMD factor UPF1 (Lareau et al., 2007; Ni et al., 2007) or treatment with the 
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translational inhibitor emetine (Ni et al., 2007) led to increased levels of inclusion of these exons 
containing the premature termination codons (PTCs) that trigger this RNA decay pathway.  A 2010 
study found that overexpression of SRSF1 regulated splicing of its own transcript to increase the 
usage the NMD linked splice isoform, which was within a UCE (Sun et al., 2010).  SRSF2 (SC35) 
was also shown to regulate its own alternative splicing by upregulating inclusion of a cassette exon 
or splicing out of a retained intron, both in the 3’ UTR, and thereby inducing NMD (Sureau et al., 
2001), both of which are associated with highly conserved sequences.  These studies concluded 
that the presence of exceptionally highly conserved sequences is associated with alternative 
splicing coupled to NMD allowing for autoregulation. 
One characteristic of ARGLU1 alternative splicing I will explore in this chapter is a retained 
intron, where the levels of one intron are much higher than all other introns in the gene.  
Additionally, I will show that the transcripts with this retained intron are localized to the nucleus.  
A recent study has defined a whole class of RNAs that have these same characteristics, retained 
introns and nuclear localization, which they have defined as ‘detained introns’ (Boutz et al., 2015).  
Notably, the majority of these detained intron transcripts were not regulated by NMD (Boutz et 
al., 2015).  ARGLU1 was identified as a ‘detained intron’ containing transcript in both mouse and 
human (Boutz et al., 2015).  This study also found that the levels of intron retention in a subset of 
these detained intron transcripts could be altered through certain treatments, such as DNA 
damaging agents or chemical inhibition of Clk kinases (Boutz et al., 2015), which phosphorylate 
SR proteins in the nucleus (Aubol et al., 2013; Colwill et al., 1996).  Furthermore, it has been 
reported that the SR proteins SRSF1 and SRSF2 have a number of retained intron isoforms that 
localize to the nucleus and are thought to contribute to homeostatic control of protein abundance 
of that gene (Sun et al., 2010; Sureau et al., 2001). 
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The recent development of tools for targeted genome manipulation, including the 
Cas9/CRISPR system, has led to methods for manipulating genomic DNA sequences with ease.  
Cas9/CRISPR is a bacterial adaptive defense against foreign nucleic acids that functions through 
an RNA guided nuclease.  This system has been co-opted for use in mammalian systems, and in 
the most basic iteration allows for simple targeting of double stranded DNA (dsDNA) breaks.  The 
most common repair pathways for dsDNA breaks is non-homologous end joining, a low fidelity 
repair system that often leads to insertions or deletions of nucleotides at the site of the dsDNA 
break. 
The hypothesis explored in this chapter is that the ultraconserved element within the 
retained intron of ARGLU1 has a regulatory role in alternative splicing of this RNA.  I will 
explore the role of this UCE in a number of different ways, including direct mutagenesis of a 
splicing minigene, Cas9/CRISPR mediated mutagenesis of the genomic loci, and an assessment of 
the role of splice site strength in the alternative splicing of this gene. 
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2.2 Results 
2.2.1 ARGLU1 is alternatively spliced and partitions to the nucleus or cytoplasm depending 
on alternative splicing 
I initially identified ARGLU1 as partitioning to the nucleus through RNA-Seq data from 
HeLa cells that had been fractionated into cytoplasmic and nuclear pools and poly(A) selected 
(LLC, LY, and GC, data not shown).  A polyadenylated ARGLU1 transcript containing a single 
retained intron, but otherwise fully spliced, was found exclusively in the nuclear fraction of cells 
I investigated (Figure 2.1).  The fully spliced isoform (see Figure 2.2 for an overview of the splice 
isoforms) is seen in both the nucleus and cytoplasm by RNA-Seq (Figure 2.1), RT-PCR (Figure 
2.3) as well as northern blot (Figure 2.4).  As mentioned previously, a number of transcripts with 
these characteristics have been identified, and have been termed detained introns (Boutz et al., 
2015).  
A minor alternative splicing product has also been observed and annotated previously in 
the Ensembl gene annotation database (Cunningham et al., 2014).  This isoform includes an 
alternative exon that lies within the retained intron.  The inclusion of this exon would be predicted 
to cause degradation by NMD, as it causes a premature termination codon (PTC).  Initial RT-PCR 
experiments see little evidence of inclusion of this isoform (Figure 2.3), possibly the result of rapid 
degradation by NMD.  I will address the degradation of transcripts including this exon in section 
2.2.6.  Furthermore, experiments below indicate that the presence of this alternative exon 
influences the level of intron retention. Furthermore, I see increased usage of this exon under 
conditions of ARGLU1 overexpression, which will be explored further later in this report.  
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Figure 2.1 A transcript with a retained intron is localizes to the nucleus and is associated 
with an ultraconserved element.  RNA-seq reads from nuclear and cytoplasmic fractions of HeLa 
cells are aligned to the RefSeq gene annotation for ARGLU1.  Nuclear reads are presented in red, 
while cytoplasmic reads are in blue.  Below the gene annotations is a view from the evolutionary 
conservation browser (Ovcharenko et al., 2004).  In this view orange represents regions of 
nucleotides that are more than 97% conserved with human for over a 200 base window, dark blue 
indicates conserved coding regions, and green indicates simple repeats.  I have noted the length of 
the regions that are 97% conserved between human and the species indicated. 
  
 
 
32 
 
Figure 2.2 Overview of the ARGLU1 isoforms studied in this dissertation.  This cartoon view 
of the gene architecture of ARGLU1 and the splice isoforms derived from the pre-mRNA.  The 
fully spliced RNA has 4 exons, and is exported to the cytoplasm.  The retained isoform contains 4 
exons as well as the retained intron 2, and is located in the nucleus.  The alternative exon included 
isoform is quickly degraded by NMD because it contains a premature termination codon, indicated 
by a red circle. 
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Figure 2.3  RT-PCR confirms that the ARGLU1 intron retained isoform is present exclusively 
in the nucleus.  A. RT-PCR was performed on nuclear and cytoplasmic fractions of the indicated 
cell types. NEAT1 is a lncRNA that is seen exclusively in the nucleus, and RPS19 primers cross 
a splice boundary and indicate the fully spliced isoform is localized exclusively in the cytoplasm. 
B. Primers used for RT-PCR of ARGLU1.  Primer set 1 is Ex2+Ex3 primers.  Primer set 2 is 
Ex2F+IntR.  Primer set 3 is Ex3R+IntF. 
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Figure 2.4 Western Blot and Northern Blot indicate that the ARGLU1 retained intron 
isoform is localized exclusively in the nucleus.  The top panel is a western blot against the nuclear 
marker TATA Binding Protein (TBP) and the cytoplasmic marker GAPDH in either total lysate 
or nuclear and cytoplasmic fractions of HEK-293 cells.  Cells were fractionated as in  Figure 2.2.  
The bottom panel is a northern blot using a probe that detects both the spliced and retained intron 
isoforms.  The spliced and retained intron isoforms are indicated in cartoon form on the right. 
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2.2.2 ARGLU1 contains an Ultraconserved Element (UCE) 
In order to identify sequences within this alternatively spliced intron I hypothesized that 
evolutionary conservation could serve as a marker for biological function.  Based on this 
hypothesis, I queried databases of highly evolutionarily conserved sequences.  Indeed, a region 
within the ARGLU1 intron has been previously identified as an ultraconserved element by the 
UCNEbase, a database of Ultraconserved Noncoding Elements which identified UCEs as stretches 
of nucleotides 95% conserved for over 200 bases between human and chicken (Dimitrieva and 
Bucher, 2013).  This represents a base substitution rate of approximately 1% per 100 million years, 
and sequences fulfilling these stringent requirements have been previously found to only exist in 
vertebrates (Retelska et al., 2007). Using UCNEbase and the Evolutionary Conserved Browser 
(Ovcharenko et al., 2004), I was able to identify an ultraconserved region of 500 bases that fit these 
requirements (Figure 2.1).  This region is 95% conserved at the nucleotide level between human 
and chicken for 500 bases, and 95% conserved with the frog xenopus tropicalis for 265 bases 
(Figure 2.1).  Notably, using the more strict definition of a UCE set out by Bejarano et al (Bejerano 
et al., 2004), which required 100% conservation for over 200, the ARGLU1 UCE is 100% 
conserved between human and chicken for 228 bases. 
2.2.3 The UCE in ARGLU1 intron 2 is a cis-regulatory element controlling intron retention 
The observation of the UCE located within the retained intron led us to hypothesize that 
this element is regulating this alternative splicing event.  To test this in an experimentally tractable 
manner, I created a splicing reporter vector comprised of the retained intron as well as the flanking 
exons, which I called A23, for ARGLU1 exons2-3 (Figure 2.5).  When transfected into HEK-293T 
cells, this vector is spliced similarly to the endogenous ARGLU1, with the retained intron mRNA 
representing approximately half of the mRNA derived from the reporter (Figure 2.6 and 2.7).  
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To test the role of the UCE in intron retention, I created a number of deletions in the 
splicing reporter vector.  I created a large deletion of 504 bp, representing the sequence 95% 
conserved with chicken.  I also made a series of three smaller deletions of 168 bp that were 
subdeletions of this large 504 bp deletion.  A control deletion was also made of the same size in a 
non-conserved region of the intron.  Using RNase protection assays, I observed that the wild type 
and control deletion reporter vector, as well as 168 bp deletion 1, showed mostly retained intron 
RNA when transfected (Figure 2.6).  However, the 504 bp UCE deletion as well as 168 bp deletions 
2 and 3 caused a dramatic increase in splicing of exons 2 and 3 (Figures 2.6 and 2.7). 
To determine specific sequences regulating ARGLU1 alternative splicing, a series of 25 
bp deletions were created spanning the 168 bp deletions 2 and 3 (Figure 2.5), which had previously 
been shown to contain regulatory sequences.  To compare spliced and retained isoforms of the 
splicing reporter, I designed a set of primers for competitive RT-PCR, in which I used a forward 
and reverse primer annealed to transcribed plasmid specific sequences flanking the insert along 
with a primer within the retained intron (Figure 2.5).  Deletions of sequences upstream and 
including the skipped alternative exon were found to increase splicing of exons 2 and 3 (Figure 
2.6 and Figure 2.7).  It should be noted that deletion 168-3, located downstream of the annotated 
alternative exon, caused increased splicing with a shifted band, indicating the inclusion of the 
alternative exon (Figure 2.7).  Intriguingly, deletion of sequences downstream of the skipped exon, 
including 168-3 and 25 bp deletions 9-11, increased the inclusion of the normally skipped 
alternative exon, with usage of different 5’-splice sites on the now included exon depending on the 
deletion (Figure 2.7).  The observation that different 5’-splice sites could be used following 
deletion of these sequences downstream of the alternative exon indicated that there might be 
alternative 5’-splice sites competing within this region as well as important regulatory sequences.  
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Figure 2.5 Diagram of the A23 splicing reporter vector.  A PCR-derived fragment that includes 
Exon2-intron 2- Exon3 was cloned into the pcDNA3 plasmid, and it was named A23, after 
ARGLU1 exons2-3.  I then confirmed that this splicing reporter recapitulated the splicing of the 
endogenous mRNA, generating both a spliced and retained intron mRNA.  I then generated a 
number of deletion mutants of this plasmid, including a 504 bp deletion of the sequence 95% 
conserved between human and chicken, as well as a 500 bp control deletion in a non-conserved 
region of the intron.  I then made three 168 bp deletions to subdivide the 504 bp deletion.  These 
were tested by RPA (Figure 2.6), and it was determined that only deletions 168-2 and 168-3 altered 
splicing.  Finally, I made a series of 25 bp deletions that spanned deletions 168-2 and 168-3.  
Primers used in subsequent RT-PCR assays are indicated as labeled arrows. 
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Figure 2.6 RNase Protection Assay indicates that elements within the UCE inhibit splicing 
of ARLGU1 exons 2 and 3.  RNA from cells transfected with the A23 splice reporter vector or 
the derivatives noted was hybridized with a body labeled probe that annealed to exon 3 into the 
retained intron.  Splicing of the reporter resulted in the lower band.  This figure represents two 
replicates. 
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Figure 2.7 Competitive RT-PCR shows that specific elements within the ARGLU1 UCE 
regulate intron retention, Exon2-3 splicing, and alternative exon inclusion.  The A23 splicing 
reporter plasmid as well as the deletion mutants were transfected into HEK-293 cells.  RNA was 
harvested and used for competitive RT-PCR.  Primers for RT-PCR are indicated in Figure 2.5.  
The bands produced from the primer sets are indicated on the right. 
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2.2.4 Analysis of putative splice sites bounding the alternative exon: 
To test what, if any, role the splice sites bounding the UCE alternative exon and the possible 
5’-splice sites downstream of this alternative exon play, I mutated these splice sites individually 
and in combination (Figure 2.8A).  Mutation of the annotated 3’ splice site of the alternative exon 
leads to decreased intron retention and increased splicing of Exon 2-Exon 3 (Figure 2.8B).  
Furthermore, plasmids with a mutation of this 3’ splice site completely lacked splicing inclusion 
of the alternative exon (Figure 2.8B).  Mutating the annotated 5’-splice site of the UCE exon did 
not drastically change the ratio of spliced to retained intron 2.  Interestingly though, it did cause 
an increase in alternative exon inclusion; however the included exon was larger, indicating the 
usage of a different 5’-splice site downstream of the normal splice site (Figure 2.8B).   
I also created mutations in six possible 5’-splice sites downstream (containing either a GT 
or GC dinucleotide), to determine which, if any, of these sequences might regulate inclusion of the 
UCE exon (Figure 2.8A).  I found that mutation of putative splice sites 2-4 did not alter the ratio 
of intron retention to spliced product.  These mutations did cause a change in the inclusion of the 
alternative exon, which was the larger of the two noted bands (Figure 2.8B).  Interestingly, 
mutation of putative splice sites 5 and 6 did alter the ratio of retained and spliced reporter, causing 
an increase in splicing.  Furthermore, these mutations caused a difference in splicing of the 
alternative exon as well, with exclusive inclusion of the smaller band (Figure 2.8B).  By 
sequencing RT-PCR products from cells transfected with these plasmids, I determined that 
mutation of SS5 and SS6 caused exclusive use of the annotated 5’-splice site.  Additionally, Sanger 
sequencing of the products from SS3 and SS4 indicated that the upper band corresponds to SS5 
(Data not shown).  Analysis for the predicted 5’-splice site using a variety of computational models 
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(Yeo and Burge, 2004) indicates that the annotated 5’-splice site is actually weaker compared to 
other 5’-splice sites analyzed, especially splice sites 5 and 6  (See Table 2.1). 
To further analyze the role of the splice sites flanking the retained intron and skipped exon, 
I improved the splice sites to match strong consensus 5’- or 3’-splice sites (Figure 2.9A).  I found 
that improvement of the 5’-splice site of exon 2 or the 3’-splice site of exon 3 did not appreciably 
increase the ratio of spliced to retained product (Figure 2.9B).  However, mutation of the 3’ splice 
site of the alternative exon dramatically increased the inclusion of the alternative exon, as indicated 
by a shift in the spliced band obtained by RT-PCR (Figure 2.9B).  As seen in previous experiments, 
there seem to be two shifted bands (Figure 2.8B), indicating that two possible 5’-splice sites can 
be used upon inclusion of the alternative exon.  Mutation of the annotated 5’-splice site of the 
alternative exon to a consensus 5’-splice site also leads to increased inclusion of this alternative 
exon by RT-PCR (Figure 2.9B).  Interestingly, there is only one band in this situation, which 
indicates usage of only one 5’-splice site, which was confirmed by Sanger sequencing to be the 
improved alternative 5’-splice site.  
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Figure 2.8 Mutagenesis of 3’- and putative 5’-splice sites downstream of the alternative exon 
modulates both intron retention and alternative exon inclusion.  A. Splice site mutation 
derivatives of the A23 splicing reporter are detailed.  The 3’ splice site of the alternative exon is 
noted in green, and 5’-splice sites are noted in red.  The 3’ splice site was mutated.  5’-splice sites 
were mutated from GU to CA.  B.  RT-PCR was performed from HEK-293 cells transfected with 
the noted splicing reporter mutant.  Two sets of PCR were performed, one with primers 
vecF+vecR+retR to assess splicing vs intron retention, and a second with altF+vecR to assess the 
5’-splice site used upon alternative exon inclusion.  At the bottom is the sequence of the region 
surrounding the alternative exon. 
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Figure 2.9 Improvement of the alternative exons, but not the constitutive exons, changes 
intron retention and alternative exon inclusion.  A. Mutations were made in the A23 splicing 
reporter to improve the splice sites of the constitutive exons 2 and 3, or the splice sites flanking 
the alternative exon.  Below the diagram is the specific sequence that was mutated.  The top line 
is the endogenous sequence, and the bottom line is the mutant sequence.  B. RT-PCR was 
performed from HEK-293 cells transfected with the noted splicing reporter plasmid.  Primers are 
indicated in Figure 2.9A and the bands are indicated on the right. 
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 Splice site 9-mer sequence MAXENT: MDD: MM: WMM: 
Alt 5' aca|GTaaat 1.91 2.98 3.33 3.74 
SS1 aat|GCtgat -20.87 -14.68 -17.9 -9.94 
SS2 gga|GTatag -7.36 1.08 0.86 -0.91 
SS3 tag|GTaaag 6.93 11.08 5.49 6.65 
SS4 tac|GTaggt 4.81 9.18 4.92 5.81 
SS5 tag|GTatac 4.69 8.18 3.68 3.41 
SS6 ttg|GTgaga 6.29 11.68 6.58 6.27 
Table 2.1 Analysis of 5’-splice site strength using various models.  Predictions were made 
using the MAXENT tool (Yeo and Burge, 2004).  
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2.2.5 Modification of the endogenous ARGLU1 UCE disrupts intron retention: 
I next sought to validate the ability of mutations and deletions within the UCE to cause 
changes in splicing.  To accomplish this I used the Cas9/CRISPR system (Ran et al., 2013) to 
generate random mutations by non-homologous end joining.  I designed two different guide RNAs 
targeting the UCE (appendix A).  I inserted these guides into a plasmid co-expressing the sgRNA 
as well as Cas9 fused to GFP by a self-cleaving PP2A polypeptide (Ran et al., 2013).  These 
plasmids were transfected into HEK-293 Flp-In T-Rex cells.  I then sorted single cells expressing 
GFP into 96 well plates and allowed them to grow until the cells formed colonies.  I was able to 
isolate a number of clones with heterozygous or compound heterozygous insertions and deletions 
within the UCE (data not shown), all of which demonstrated increased splicing and decreased 
levels of ARGLU1 intron retention compared with wild-type cells (Figure 2.10).  Clone 4 showed 
the largest increase in the ratio of spliced/retained intron, and contained a homozygous single 
nucleotide insertion within the alternative skipped exon (Figure 2.10).  However, other interesting 
clones were also obtained.  For example, clone 14 contained a single nucleotide homozygous 
deletion within the alternative exon that caused inclusion of this alternative to be frame 
maintaining, thus stabilizing mRNAs that contained the alternative exon (Figure 2.10).  Finally, 
clone 3 had a large heterozygous insertion within the alternative exon that caused increased 
inclusion of the alternative exon (Figure 2.10. 
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Figure 2.10 Disruption of the UCE at the endogenous chromosomal locus disrupts intron 
retention vs splicing.  A.  Primers used for RT-PCR.  B.  RT-PCR of RNA from clonal HEK-293 
cell lines in which Cas9/CRISPR was used to target double stranded breaks to the alternative exon 
in the UCE.  A number of clones were recovered that had a mixture of insertions and deletions.  
Clone 4 contains a homozygous single nucleotide insertion in the UCE that dramatically increased 
splicing and decreased intron retention.  Clone 3 included a large insertion in the UCE that 
increases inclusion of the alternative exon including the insertion (noted by a *).  Clone 14 contains 
a single nucleotide deletion that causes the alternative exon to be in frame, causing transcripts 
including the alternative exon to be stabilized.  The included alternative exon is noted by a †).  C. 
Chromatograph from Clone 4 indicating a single nucleotide insertion in the alternative exon in the 
UCE. 
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2.2.6 ARGLU1 intron 2 is sufficient to induce intron retention in an exogenous context 
 Previous experiments have shown that the UCE in the ARGLU1 intron 2 is necessary for 
intron retention or inhibition of splicing.  However, we next wanted to ask whether the ARGLU1 
intron could cause splicing inhibition in an exogenous context.  To that end, I cloned the ARLGU1 
intron 2 into the pzw1 vector in either the forward or reverse direction.  The pzw1 vector consists 
of an EGFP cDNA with an intron containing a multiple cloning site in the middle of the GFP 
critical fluorescent site.  The intron is inefficiently spliced, but the addition of sequences into the 
exon has been used to determine sequences that modify exon splicing (Wang et al., 2004).  I found 
that the forward ARGLU1 insert, but not the reverse insert, was sufficient to generate a band 
consistent with the retained intron.  However, the majority of the RT-PCR product indicated 
splicing, possibly because the 5’- and 3’-splice sites in the vector are quite strong. 
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Figure 2.11 ARGLU1 intron 2 is sufficient to induce intron retention in an exogenous context.  
The pzw1 vector contains an intron with an MCS in the middle of EGFP.  ARGLU1 intron 2 was 
inserted into this MCS in either a forward (intF) or reverse (intR) direction (i.e. the reverse 
compliment as a size-matched control).  These plasmids were transfected into HEK-293 cells, and 
RNA was harvested 24 hours later.  RT-PCR using competitive PCR with the primers indicated 
can detect a band produced by splicing as well as one consistent with intron retention. 
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2.3 Conclusion: 
I have identified ARGLU1 as a transcript that has a number of interesting characteristics.  
First, it has a retained intron, a form of alternative splicing relatively rare and poorly understood 
in mammals.  Second, the ARGLU1 isoform containing the retained intron is localized exclusively 
in the nucleus.  These two characteristics have recently been used to define a class of mRNAs 
labeled ‘detained introns’ (Boutz et al., 2015).  That study identified ARLGU1 as a detained intron 
in both human and mouse cells (Boutz et al., 2015).  I have shown through multiple methods, 
including RNA-seq, RT-PCR and northern blot that the retained intron ARGLU1 transcript is 
abundant and exclusively nuclear.  Additionally, it does not seem to be sensitive to NMD, as 
treatment with emetine did not increase the abundance of the retained intron isoform.  Insensitivity 
to NMD was another characteristic used by Boutz et al. (Boutz et al., 2015) to functionally separate 
‘detained introns’ from transcripts with retained introns that were exported from the nucleus and 
degraded by NMD.  The third intriguing characteristic of ARGLU1 is that there is a UCE 
associated with the retained intron.  As mentioned previously, the presence of UCEs has been 
linked to alternative splicing and homeostatic regulation of SR proteins (Lareau et al., 2007; Ni et 
al., 2007; Sun et al., 2010; Sureau et al., 2001). 
In this chapter I have defined many of the cis-regulatory elements that control alternative 
splicing of ARGLU1.  In line with previous reports that UCEs are associated with alternative 
splicing linked to NMD (Lareau et al., 2007; Ni et al., 2007), I have shown that there is an NMD 
sensitive alternative exon that lies completely within the ARLGU1 UCE.  However, unlike 
previous studies of these UCE-linked alternative splicing events, I have experimentally tested the 
role of sequences within the UCE to show this sequence is both necessary and sufficient to induce 
intron retention. 
 
 
50 
 
The presence of the alternative exon within the retained intron of ARGLU1 seems to be 
central to the regulation of intron retention.  Deletion of sequences that overlap the alternative exon 
cause a dramatic decrease in the level of intron retention relative to splicing of exon2-exon3.  
Mutation of the 3’-splice site of the alternative exon causes a dramatic increase in exon2-exon3 
splicing and a decrease in intron retention. Furthermore, deletion or mutation of sequences 
downstream of the alternative exon also seem to regulate splicing of exon2-exon3.  In particular, 
mutation of two 5’ss-like sequences downstream of the alternative exon (SS5/SS6) seem to 
dramatically increase splicing exon2-exon3.  Conversely, mutation of two different 5’ss-like 
sequences in downstream of the alternative exon cause increased usage of the alternative exon, but 
changes the 5’ss of the alterative exon to SS5. 
On the other hand, improving the annotated splice sites flanking the alternative exon causes 
a marked increase in the usage of the alternative exon.  In particular, mutation of the 3’-splice site 
and addition of upstream pyrimidine caused a dramatic increase in the alternative exon usage, 
albeit with evidence of multiple 5’-splice sites, in line with previous results.  Interestingly, 
improvement of the annotated 5’-splice site alone also increased inclusion of the alternative exon, 
but with usage of that splice site alone. 
These data suggest a complicated cis-regulatory environment centered on the presence of 
an alternative exon.  Based on the fact that improvement of either the 3’ or 5’-splice site of the 
alternative exon shifts splicing almost exclusively to the inclusion of that exon, I propose that there 
is poor exon definition of the alternative exon.  However, the mutagenesis of sequences 
downstream of the alternative exon indicate that there are other regulatory elements that seem to 
function as both intronic and exonic splice suppressors.  The sequences at SS3 and SS4 seem to 
increase usage of the SS5 putative 5’ss at the expense of the annotated 5’-splice site, indicating 
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that these sequences may act as intronic splice silencers.  Conversely, mutation of SS5 and SS6 
sequences cause the sole use of the annotated 5’ss of the alternative exon, and also increase exon2-
exon3 splicing.  This indicates that the presence of at least one competing 5’ss downstream of the 
alternative exon is important for regulation of intron retention versus exon2-exon3 splicing.  I 
therefore suggest that the combination of weak splice sites flanking the alternative exon as well as 
multiple putative 5’-splice sites downstream of this alternative exon causes poor exon definition, 
but is sufficient to act as a decoy for productive splicing of the upstream and downstream exons.  
This decoy exon may then form splicing complexes that are not able to be completed, and thus 
lead to intron retention. 
This model seems to be in line with a previously proposed model of intron retention 
(Sakabe and de Souza, 2007).  The improper exon definition model of intron retention is based on 
failure of complete exon definition.  The exons flanking the retained intron are defined by 
interactions of cis- and trans-factors.  However, after this exon definition step, these defined exons 
go on to associate and remove the intron, or fail to associate and thus retain the intron.  This failure 
would be presumed to occur as a result of the spliceosome failing to transition from complex E to 
A, indicating that not all of the important exonic sites were recognized, or from a failure in 
transition from complex A to B, indicating that the 5’-and 3’ splice sites were not brought together.  
A number of trans-factors have been shown to inhibit the assembly of the E complex, including 
hnRNPA1 (Yu et al., 2008).  Interestingly, SRSF7, which normally stimulates exon inclusion, can 
play an inhibitory role if it binds intronic sequences proximal to exons, and was shown to inhibit 
progression past the spliceosomal E complex (Erkelenz et al., 2013).  Other proteins have been 
shown to prevent the rearrangement of the spliceosome beyond the A complex, including PTB 
(Sharma et al., 2008, 2011). 
 
 
52 
 
2.4 Materials and Methods 
Cell Culture 
HEK-293 cells were maintained in DMEM supplemented with 10% fetal bovine serum and 100 
U/mL Penicillin-Streptomycin.  Cells were grown at 37°C, in an environment maintained at 5% 
CO2. 
Nuclear/Cyotplasmic Fractionation 
Nuclear/Cyotplasmic fractionation was carried out as in (Chen et al., 2008) with some 
modifications.  10 cm dishes of cells were washed twice with ice-cold PBS.  These cells were then 
harvested by scraping in ice-cold PBS and pelleted by centrifugation at 1000 x g for 5 minutes at 
4°C.  Cells were then gently resuspended in 250 uL of lysis buffer A (10 mM Tris (pH 8.0), 140 
mM NaCl, 1.5 mM MgCl2, 0.5% Igepal, 2 mM vanadyl ribonucleoside complex (VRC; 
Invitrogen)) and incubated on ice for 5 minutes.  During this incubation 1/10th of the total cell 
lysate was retained for western blotting and 1/5th of the whole cell lysate was added to 1 mL of 
Trizol reagent.  The rest of the lysate was centrifuged for 3 minutes at 4°C to pellet the nuclei.  The 
supernatant was reserved as the cytoplasmic fraction, and was spun a second time to remove any 
remaining nuclei.  1/5th of the cytoplasmic fraction was then used for western blot, while the 
remaining fraction was added to 1 mL of Trizol reagent.  The remaining nuclear pellet was washed 
2X with 300 uL lysis buffer A, then the nuclei were resuspended in 100 uL of lysis buffer A, 1/5th 
of the nuclear lysate was used for western blot and the remaining nuclear fraction was added to  1 
mL of Trizol reagent. 
Northern Blotting 
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10 ug of RNA was used for loading onto a 1% agarose in sodium phosphate buffer.   RNAs were 
resuspended in a RNA gel loading buffer containing glyoxal, bromophenol blue and xylene cyanol.  
RNAs were denatured at 75 C for 3 minutes, then loaded into the gel.  The RNAs were resolved 
at 90 volts for 1 hour.  RNA was then transferred to positively charged nylon membrane using 
capillary transfer in 20X SSC for 4 hours.  After transfer, the membrane was crosslinked to the 
membrane using 1200 mJ UV 285 nm irradiation.  The membrane was then blocked using Ambion 
Northern Max hybridization buffer.  The membrane was then hybridized over night with an RNA 
probe against a region common to both the sliced and intron retained isoforms that was internally 
labeled with biotin.  The membrane was then washed first with low stringency wash buffer 1X, 
and high stringency buffer 2X.  The probes were detected with alkaline phosphatase conjugated 
streptavidin and illuminated with CDP-star chemiluminescent reagent. 
Plasmids  
The A23 plasmid was created using a pcDNA3 vector backbone.  A PCR fragment consisting of 
the genomic region spanning ARLGU1 exon 2 to exon 3, including the intron, was TA cloned into 
the TOPO 2.1 vector, thus the name A23.  A clone was selected that did not show any mutations 
within the UCE or within 300 bases of either exon.  The A23 fragment was excised from the TOPO 
2.1 vector using EcoRI, which cleaves on both sides of the fragment, and cloned into the pcDNA3 
expression vector also cut with EcoRI.  This resulted in both forward and reverse inserts into the 
pcDNA3 vector.  A number of clones were obtained for each direction, and clones were again 
screened with Sanger sequencing to ensure no mutations in the UCE or within 300 bases of either 
exon.  The forward pcDNA A23 clone #3 was then used for future experiments.  All other A23 
mutants were derivatives of this initial plasmid. 
Mutagenesis 
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Mutagenesis was carried out using the Q5 mutagenesis protocol.  Briefly, PCR of circular plasmids 
was carried out with non-overlapping opposing forward and reverse primers that together 
contained the mutation or flanked the area to be deleted.  The PCR products were then treated with 
a mixture of T4 PNK, DpnI nuclease, and T4 DNA ligase.  This mixture was then transformed into 
DH5α E. coli.  Mutations were confirmed by Sanger sequencing.  Primers used for each mutagnesis 
are listed in appendix A. 
RNase Protection Assay 
RPAs were carried out using the Ambion RPA III kit according to the manufacturer’s instructions.  
Labeled RNA probes were generated from an A23 plasmid with a reverse insert using the plasmid 
T7 promoter and internally labeled with Biotin-UTP.  The RNA probes were then denatured and 
hybridized overnight to RNA from cells transfected with the A23 reporter plasmids.  Non-
hybridizes RNA was then digested with a mixture of RNase A and T1.  The RNAs were then 
purified and resolved on a 5% TBE-urea polyacrylamide gel.  The protected fragments were 
transferred to positively charged nylon membrane, and probed with an alkaline phosphatase 
conjugated streptavidin.  The chemiluminescent reagent CDP-star was used to expose the bands.  
The membrane was then imaged on a Kodak Image Station machine. 
Preparation of RNA 
RNA was prepared by lysing cells in an appropriate volume of Trizol (Life Tech).  Chloroform 
was added, mixed vigorously, and incubated on ice for 5 minutes.  These samples were centrifuged 
at maximum speed for 15 minutes.  The aqueous phase was then recovered and precipitated by the 
addition of equal volume 100% isopropanol with glycoblue carrier added.  The RNA pellet was 
then washed 1X with 75% ethanol and resuspended in an appropriate volume of RNase free water.  
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RNA concentration was assessed using Absorbance at 280 on a nanodrop spectrophotometer.  5 
ug of RNA was treated with Ambion Turbo-DNA free DNase I reagent, and collected into fresh 
tube following treatment with the Ambion DNase I inactivation reagent. 
RT-PCR 
Reverse transcription was carried out on DNase I treated RNA using the Protoscript II cDNA 
synthesis kit using random primers (New England Biolabs).  PCR was then carried out using 
OneTaq quick load master mix (NEB) with the primers indicated for each experiment.  RT- 
samples were also used as a control for all PCR sample to test for residual DNA.  Primers can be 
found in Appendix A. 
Cas9/CRISPR 
I used the px458 plasmid (Ran et al., 2013) in order to generate site directed double stranded breaks 
in the UCE.  This plasmid contains the Cas9 nuclease fused to GFP with a self-cleaving PP2A 
peptide, causing transfected cells to fluoresce when Cas9 is expressed.  I cloned 2 separate guide 
RNAs into the expression plasmid, and transfected them into HEK-293 Flp-In TRex cells.  After 
24 hours, cells were FACS sorted and cells were plated into individual wells 96 well plates.  After 
growing cells to obtain clonal colonies, cells were screened with PCR and sequencing of the 
genomic region surrounding the targeted sites.  RT-PCR was carried out using primers in exon2F 
and exon3R, listed in appendix A.  
Western blotting 
Cells were lysed for 30 minutes in ice cold RIPA buffer supplemented with protease inhibitors and 
benzonase.  Protein was quantified using the BioRad Cell lysates were then mixed with 2X 
Laemmli’s SDS loading buffer with 10 mM DTT.  30 µg of protein was loaded into SDS-PAGE 
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gels and resolved at 100V.  Transfer to nitrocellulose membrane was carried out in Tris-glycine 
buffer with 10% methanol at 4°C at 240 mA for 2 hour.  Membranes were blocked with Licor 
blocking buffer for 1 hr at room temperature.  Blots were then incubated overnight at 4°C with 
primary antibody diluted (TBP 1:1000, GAPDH 1:2000) in Licor blocking buffer supplemented 
with 0.1% tween-20.  Membrane was then washed with TBS-0.1% tween 3 times for five minutes. 
Appropriate florescent labeled secondary antibodies diluted in Licor blocking buffer with 0.1% 
tween and 0.01% SDS were incubated with the membrane for 45 minutes at room temperature 
with rocking.  Membrane was then washed with TBS-0.1% tween 3 times for five minutes.  
Membranes were imaged on the Licor Odyssey system. 
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Chapter 3 
ARGLU1 Protein Regulates the Splicing of its own mRNA 
3.1 Introduction 
This chapter will focus on the homeostatic regulation of ARGLU1 mRNA splicing.  As 
described in the previous chapter, an ultraconserved element (UCE) is associated with the complex 
alternative splicing of ARGLU1 through the regulation of an alternatively spliced in exon as well 
as a retained intron.   
Previous studies have indicated that UCEs and other highly conserved elements, are often 
associated with alternative splicing events (Baek and Green, 2005; Lareau et al., 2007; Ni et al., 
2007).  Interestingly, SR proteins, a class of proteins known to promote RNA splicing and 
implicated in alternative splicing, are enriched for highly conserved sequences around exons that 
are alternatively spliced.  A number of studies have indicated that SR proteins can cause feedback 
loops that act to regulate splicing of their own mRNAs, and consequently protein levels, including 
SRSF1 (Sun et al., 2010) and SRSF2 (Sureau et al., 2001). 
These highly-conserved element-associated alternative splicing events are often linked 
with a process known as nonsense-mediated decay (NMD).  NMD is a cellular quality control 
mechanism that functions to degrade mRNA transcripts containing aberrant premature termination 
codons (PTCs).  These PTCs are recognized by the presence of a complex known as the Exon 
Junction Complex (EJC), which is a group of proteins deposited 24 bases upstream an exon-exon 
junction (Le Hir et al., 2001; Shibuya et al., 2004).  The EJC is important for nuclear export of 
spliced RNAs (Le Hir et al., 2001; Schell et al., 2002) and translation (Nott et al., 2004).  However 
it also serves as a platform for the assembly of the NMD machinery.  UPF1 is one of the major 
components of the NMD pathway and is recruited to stop codongs along with another NMD factor, 
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SMG1, and the release factors eRF1 and eRF3 (collectively known as the SURF complex) 
(Kashima et al., 2006).  If an exon junction complex is present more than approximately 50 bases 
downstream of this stop codon, an interaction between the SURF complex and UPF2 in the EJC 
will lead to phosphorylation of UPF1 (Chamieh et al., 2008), leading to recruitment of the 
endonuclease SMG6 and consequently RNA degradation (Kervestin and Jacobson, 2012). 
In this chapter, I will test the hypothesis that ARGLU1 protein has a regulatory role 
on the splicing of its own mRNA.  Based on previous findings that the highly conserved 
sequences around the alternative exon are important for regulation of ARGLU1 spicing, I propose 
that the ARGLU1 protein itself may function to regulate this splicing event.  To test this 
hypothesis, I have designed a cell line that allows expression of ARGLU1 protein in a tetracycline-
inducible manner.  Using this system, I have assessed the impact of ARGLU1 overexpression on 
the splicing of the endogenous ARLGU1 mRNA transcripts, causing a decrease in exon2-exon3 
splicing and an increase in inclusion of the alternative exon that is subject to NMD.  Conversely, 
I will show that inhibition of protein synthesis is associated with splicing regulation opposite of 
that seen with ARGLU1 overexpression. 
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3.2 Results 
3.2.1 ARGLU1 overexpression alters splicing of the A23 splicing reporter 
 I hypothesized that one role of the UCE in ARGLU1 splicing could be to regulate protein 
expression levels through alternative splicing.  This would suggest that ARGLU1 protein might 
feedback to alter splicing of its own RNA.  To test this hypothesis, I tested the effect of a plasmid 
encoding an ARGLU1 cDNA on the splicing of the A23 splicing reporter vector (Figure 3.1A).  I 
mock-transfected, or co-transfected the ARGLU1 cDNA expressing plasmid with the WT A23 
reporter, the control deletion A23 reporter, or the 504 bp deletion reporter (Figure 3.1B).  Similar 
to previous experiments, in cells not transfected with the ARGLU1 cDNA plasmid I saw that the 
504 bp UCE deletion caused increased splicing of the reporter transcript compared with the WT 
reporter, while the control deletion did not (Figure 3.1B).  However, in cells transfected with the 
ARGLU1 cDNA, the WT and control deletion reporter transcripts had a decreased ratio of 
spliced/retained compared with the cells not transfected with the ARGLU1 cDNA plasmid (Figure 
3.1B).  The 504 bp UCE deletion reporter had an increased ratio of spliced/retained transcript, and 
was not affected by the transfection of ARGLU1 cDNA (Figure 3.1B). 
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Figure 3. 1 Transient transfection of ARGLU1 protein alters splicing of the A23 splicing 
reporter. A. Diagram of the A23 splicing reporter vector with the 504 bp and control deletion 
noted.  Primers for 3.1B are noted B. The A23 WT, A23 504 bp deletion, or Control Deletion 
splicing reporter plasmids were co-transfected with either a plasmid overexpressing ARGLU1 
cDNA or empty vector.  Splicing was assessed with the use of 3 primers, vecF, vecR, and RetR, 
seen in Figure 3.1A. 
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3.2.2 Inducible overexpression of ARGLU1 decreases endogenous ARGLU1 protein and 
alters splicing of the endogenous ARGLU1 mRNA  
To test whether this finding also held true for the endogenous transcript, I created a stable cell line 
that overexpressed ARGLU1 in a tetracycline-inducible manner.  Using the HEK-293 Flp-In TRex 
cell line, I made cell lines expressing ARGLU1, ARGLU1 with a C-terminal HA tag, or the gene 
chloramphenicol acetyltransferase (CAT) as a control (Figure 3.2).  Induction of ARGLU1 
overexpression for 24 hours with 1 µg/mL of tetracycline caused a dramatic overexpression of 
ARGLU1 protein (Figure 3.3).  Intriguingly, I found that overexpression of the HA-tagged version 
of ARGLU1, which migrates slightly slower by SDS-PAGE, led to a dramatic decrease in the level 
of the endogenous protein (Figure 3.3).  This suggested to us that ARGLU1 protein leads to 
feedback that maintains ARGLU1 protein levels.  Based on previous findings, I hypothesized that 
this could occur through regulation of alternative splicing. Indeed, quantitative RT-PCR analysis 
of splicing of the endogenous transcript after 24 hours of induction indicated that there was a 6-
fold decrease in the fully spliced endogenous transcript, and 1.6-fold increase in the retained intron 
transcript (Figure 3.4).  These changes were also observed by semi-quantitative RT-PCR using 
primers that captured both the spliced and retained transcripts (Figure 3.5).  Intriguingly, 
overexpression of ARGLU1 caused not only an increase in intron retention and a decrease in the 
spliced isoform, but also appeared to increase the inclusion of the alternative exon (Figure 3.4). 
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Figure 3.2 293 Flp-In TRex inducible expression of ARGLU1.  This is a representation of the 
Flp-In T-Rex system (Life Technologies). The Flp-In component is created using the 
pcDNA5/FRT/TO plasmid containing the gene of interest fused to a CMV promoter with two 
tetracycline operator (TetO) sequences.  The vector also has a FRT site adjacent to a hygromycin 
resistance gene.  This plasmid can be recombined at a single stably integrated FRT site, which then 
drives the hygromycin resistance gene.  There is a separate stably integrated component that 
constitutively expresses the tetracycline repressor (TetR) and is under blastcidin selection.  The 
TetR gene will bind to TetO in the absence of tetracycline/doxacycline, repressing expression of 
the gene of interest.  Addition of tetracycline will cause a conformational change in the TetR, 
releasing it from the TetO and allowing transcription of the gene of interest.  I have made 3 stable 
cell lines with this system, expressing ARGLU1 cDNA (ARGLU1-TO), ARGLU1-HA cDNA 
(ARGLU1-HA-TO), and CAT cDNA (CAT-TO) as a control. 
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Figure 3.3 ARGLU1 overexpression from the  293 Flp-In T-Rex derived cell lines.  Cell lines 
with inducible induction of either CAT (CAT-TO), HA tagged ARGLU1 cDNA (ARGLU1-HA-
TO), or ARGLU1 cDNA (ARGLU1-TO) were either induced with 1 ug/ml tetracycline (+tet) or 
mock treated (-tet) for 24 hours.  Western blot was performed with antibodies against alpha-tubulin 
as a loading control and ARGLU1.  Note that the endogenous ARGLU1 band is not present 
following ARGLU1-HA overexpression. 
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Figure 3.4 ARGLU1 overexpression increases levels of retained intron mRNA and decreases 
levels of spliced mRNA  A. Primers used for RT-qPCR in B, as well as elsewhere.  Ex2F+UTR-
R are used to measure ARLGU1 endogenous spliced mRNA, and ex2F+IntR are used to measure 
ARGLU1 retained intron mRNA.  B. RT-qPCR of the indicated HEK-293 Flp-In derived cell lines 
(Control is CAT-TO) either induced 1 µg/ml tetracycline (+tet) or mock treated (-tet) for 24 hours.  
mRNA levels are normalized to actin, and set relative to ARGLU1-TO –tet.  Sample n=3, and 
error bars represent SEM. 
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Figure 3.5 Induced overexpression of ARLGU1 causes a dramatic shift in endogenous 
ARGLU1 splicing A.  Primers used for semi-quantitative RT-PCR. B. Semi-quantitative PCR was 
performed on RNA from ARGLU1-TO cells either induced with 1 µg/ml tetracycline (+tet) or 
mock treated (-tet) for 24 hours.  RNA was then used for RT-PCR with a long extension time to 
capture all potential spliced isoforms, including fully spliced, retained intron, and alternative exon 
inclusion.  Lanes 1 and 2 are replicates of mock treated cells.  Lanes 3 and 4 are replicates of 1 
ug/ml tetracycline treated cells.  
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3.2.3 Changes in ARGLU1 splicing correspond closely with ARGLU1 protein levels 
I next tested how quickly these splicing changes occurred in ARLGU1 following induced 
overexpression of the ARGLU1-HA protein.  Using an HA-tagged ARGLU1 construct allowed 
me to assess and correlate ARGLU1 protein level in the cell with the splicing status of the 
endogenous ARGLU1 mRNA.  I found that following induction of ARLGU1-HA the endogenous 
mRNA showed a significant decrease in the spliced isoform to approximately 35% of baseline 
levels, with no change in the retained intron isoform (Figure 3.6A).  This was seen as early as 2 
hours after induction, when ARGLU1-HA levels were only 75% of endogenous levels, and total 
ARGLU1 protein levels were approximately 1.8 times baseline (Figure 3.6B).  With continued 
expression of ARGLU1-HA, levels of the endogenous spliced ARGLU1 mRNA continued to 
decrease, with a concomitant decrease in the endogenous protein (Figure 3.6A, B).  This indicated 
an inverse correlation between total ARGLU1 protein levels and the level of spliced ARGLU1 
mRNA. 
To test the hypothesis that ARGLU1 protein levels correlate with splicing of ARGLU1 
mRNA, I used emetine to inhibit translation of new proteins.  This led to rapid turnover of 
ARGLU1, with a protein half-life of approximately 4 hours (Figure 3.7B).  Using qRT-PCR to 
determine the levels of the spliced and retained intron isoforms of ARGLU1, I saw a dramatic 2.7-
fold increase in the spliced product with a concurrent decrease in the retained intron isoform after 
4 hours of treatment with emetine (Figure 3.7A). Taken together with the splicing changes seen 
following overexpression of ARGLU1 protein, this suggests that ARGLU1 maintains homeostatic 
control of its own protein level by regulating splicing of its ARGLU1 mRNA. 
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Figure 3.6 ARGLU1-HA overexpression rapidly alters endogenous ARGLU1 splicing  
A.  RT-qPCR was performed using the primer sets detailed in figure 3.4A for the spliced and 
retained intron isoforms.  RNA was harvested from ARGLU1-HA-TO cells at 2,4, and 8 hours 
following 1 µg/mL tetracycline induction, as well as from mock treated cells.  For each time point 
n=3 and error bars represent the SEM.  B. Protein quantification of ARGLU1 and ARGLU1-HA 
based on western blotting with an ARGLU1-antibody.  Protein levels were normalized to tubulin 
and set relative to the endogenous protein level at time 0.  For each time point n=3 and error bars 
represent the SEM. 
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Figure 3.7 Inhibition of protein translation causes dramatic changes in ARLGU1 splicing 
A. RT-qPCR was performed using the primer sets detailed in figure 3.4A for the spliced and 
retained intron isoforms.  RNA was harvested from HEK-293 cells at 1, 2, and 4 hours following 
1 µg/mL tetracycline induction, as well as from mock treated cells.  For each time point n=3 and 
error bars represent the SEM.  B. Protein quantification of ARGLU1 based on western blotting 
with an ARGLU1-antibody.  Protein levels were normalized to tubulin and set relative to the 
endogenous protein level at time.  For each time point n=3 and error bars represent the SEM. 
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3.2.4 Inhibition of translation increases splicing of the protein coding isoform and stabilizes 
an isoform containing the alternative exon: 
Emetine has been used to study transcripts subject to degradation through NMD (Ni et al., 
2007; Noensie and Dietz, 2001), which is dependent on the pioneer round of translation.  Given 
that emetine leads to decreased levels of NMD, it would be expected that mRNA levels of NMD 
targets should increase following treatment with emetine.  I therefore performed semi-quantitative 
PCR on cells treated with 50 µg/mL emetine or mock treated for 4 hours to assess the stability of 
the spliced isoform, retained intron isoform, and alternative exon included isoform.  Semi-
quantitative RT-PCR showed that the spliced isoform is increased (Figure 3.8B), in agreement 
previous experiments shown in figure 3.7A.  However, I found that the ARGLU1 retained intron 
RNA levels decreased by 45% compared to untreated cells after 4 hours of treatment (Figure 3.7), 
in contrast to the expected result if this transcript was subject to NMD.  Furthermore, 4 hour 
treatment with emetine caused stabilization of transcripts containing the alternative exon, 
indicating that it is subject to NMD as predicted (Figure 3.8B).   
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Figure 3.8 RT-PCR from cells treated with emetine shows stabilization of the alternative 
exon containing RNA.  A. Primers used for semi-quantitative RT-PCR.  Primers ex2F and UTR-
R were used to look at the spliced mRNA.  Primers UTR-R and altF were used to assess alternative 
exon inclusion, and also captured the retained intron isoform.  B. RT-PCR was performed from 
cells treated with 50 µg/mL emetine (4 Hr emetine) or mock treated (-emetine) for 4 hours.  
ARGLU1 spliced isoform is seen in the top panel.  The retained intron and alternative exon 
inclusion isoforms are seen in the middle panels, and actin is seen in the bottom panel.  Lanes 1 
and 2 are replicates of mock treatment and lanes 3 and 4 are replicates of emetine treatment. 
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3.3 Conclusion 
In this chapter I have addressed the role of ARGLU1 protein in the regulation of its own 
splicing.  As mentioned previously, splicing regulation takes place through cis/trans interactions.  
In the previous chapter I have described the role of a cis element that regulates splicing of 
ARGLU1.  However, the trans-regulatory factors involved in this alternative splicing were not 
clear.  I developed a hypothesis based on different lines of evidence.  First, ARGLU1 contains an 
N-terminal domain that contains a number of SR dipeptides, an essential motif in SR and SR-like 
proteins.  Second, ARGLU1 physically interacts with (Hegele et al., 2012), and is phosphorylated 
by (Varjosalo et al., 2013), SRPK1 and SRPK2, kinases that are known to regulate the activity of 
the SR splicing factor proteins.  Third, as demonstrated in the previous chapter, ARGLU1 has a 
UCE that is associated with the regulated inclusion of an alternative exon predicted to lead to 
NMD, a characteristic shared by many splicing factors (Lareau et al., 2007; Ni et al., 2007). 
Finally, a number of SR proteins have been shown to feedback and regulate the splicing of their 
own mRNAs to increase UCE associated exons containing PTCs that lead to degradation through 
NMD (Sun et al., 2010; Sureau et al., 2001).  Based on these data, I formed the hypothesis that 
ARGLU1 may function as a regulator of splicing, and feedback to alter the splicing of its own 
mRNA.   
To test this hypothesis, I used an inducible system to overexpress ARGLU1 cDNA to 
determine the impact of the ARGLU1 protein on splicing of the endogenous mRNA.  Using this 
system I have shown that, in agreement with my hypothesis, ARGLU1 overexpression 
dramatically altered the splicing of the endogenous by decreasing the spliced mRNA expected to 
code for the protein, increasing the retained intron isoform, as well as increasing inclusion of the 
alternative exon that leads to degradation through NMD. 
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3.4 Materials and Methods 
Cell Culture 
HEK 293-Flp-In TRex cells were maintained in DMEM with 10% FBS and 100 U/mL Penicillin-
Streptomycin.  Cells in which the pcDNA5/FRT vector had been integrated were additionally 
maintained in media supplemented with 15 ug/mL Blastcidin and  150 ug/mL Hygromycin B.  
Induction of protein expression was performed by supplementing DMEM/Blast/Hygromycin 
media with 1 ug/mL tetracycline for the times indicated in the text. 
Plasmids 
A cDNA for ARGLU1 was cloned into the pcDNA3 expression vector using primers detailed in 
appendix A.  This plasmid was used for the initial experiments for co-transfection with the A23 
reporter plasmids, detailed in chapter 2.  A C-terminal HA tag was added to the pcDNA3-ARGLU1 
clone using Q5 site directed mutagenesis using primers found in appendix A.  The ARGLU1 and 
ARGLU1-HA cDNA fragments were then cloned into the MCS of the pcDNA5/FRT/TO vector 
to generate pcDNA5/FRT/ARGLU1-TO and pcDNA5/FRT/ARGLU1-HA-TO plasmids.  These 
plasmids, as well as the pcDNA5/FRT/CAT-TO plasmids, were individually transfected into 
HEK-293 Flp-In TRex cells along with the poG44 plasmid, which expressed FLP recombinase, to 
mediate stable integration into the genomic FRT site.  These cells were then selected as noted 
above. 
Emetine treatment 
Cells were switched to DMEM 10% FBS supplemented with 50 ug/mL emetine for the time 
indicated in the text.  Mock treated cells received fresh media with no emetine. 
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Western blotting 
Cells were lysed for 30 minutes in ice cold RIPA buffer supplemented with protease inhibitors and 
benzonase.  Protein was quantified using the BioRad protein quantification kit.   
Cell lysates were then mixed with 2X Laemmli’s SDS loading buffer with 10 mM DTT.  30 µg of 
protein was loaded into SDS-PAGE gels and resolved at 100V.  Transfer to nitrocellulose 
membrane was carried out in Tris-glycine buffer with 10% methanol at 4°C at 240 mA for 2 hour.  
Membranes were blocked with Licor blocking buffer for 1 hr at room temperature.  Blots were 
then incubated overnight at 4°C with primary antibody diluted (ARGLU1 1:1000, Tubulin 1:1000) 
in Licor blocking buffer supplemented with 0.1% tween-20.  Membrane was then washed with 
TBS-0.1% tween 3 times for five minutes. Appropriate florescent labeled secondary antibodies 
diluted in Licor blocking buffer with 0.1% tween and 0.01% SDS were incubated with the 
membrane for 45 minutes at room temperature with rocking.  Membrane was then washed with 
TBS-0.1% tween 3 times for five minutes.  Membranes were imaged on the Licor Odyssey system. 
Preparation of RNA 
RNA was prepared by lysing cells in an appropriate volume of Trizol (Life Tech).  Chloroform 
was added, mixed vigorously, and incubated on ice for 5 minutes.  These samples were centrifuged 
at maximum speed for 15 minutes.  The aqueous phase was then mixed with 70% ethanol and 
processed with the Purelink RNA mini kit according to the manufacturer’s instructions.  RNAs 
were treated with Purelink On-column DNase I.  RNA concentration was assessed using 
Absorbance at 280 on a nanodrop spectrophotometer. 
RT-PCR and RT-qPCR 
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RT was performed on DNase I treated RNA using the Protoscript II cDNA synthesis kit (NEB) 
with random primers.  Semi-quantitative RT-PCR was carried out using OneTaq 2X mastermix 
(NEB) according to the manufacturer’s instructions.  RT-PCR products were resolved in 2% 
agarose TAE gels stained with ethidium bromide.  RT-qPCR was carried out using iTaq Universal 
SYBR Green Supermix on the CFX96 qPCR platform.  Primers used in RT-PCR and RT-qPCR 
are listed in appendix A. 
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Chapter 4 
ARGLU1 Overexpression Alters the Expression Level and Alternative Splicing of a Subset 
of Genes 
4.1 Introduction 
In the previous chapter I have shown evidence that ARGLU1 protein levels are controlled 
through a negative feedback loop, where high levels of ARGLU1 protein induce complex 
alternative splicing of the ARGLU1 transcript that ultimately results in lower levels of ARGLU1 
protein.  Overexpression of ARGLU1 increases the inclusion of an alternative exon that appears 
to lead to NMD degradation through the inclusion of a premature termination codon, increases 
intron retention of a transcript that is detained in the nucleus, while at the same time decreasing 
levels of the mature transcript that codes for the ARGLU1 protein.  Additionally, ARGLU1 has 
been found to physically associate with a number of proteins involved in splicing, including in 
affinity purification of the spliceosome (Behzadnia et al., 2007; Bessonov et al., 2008; Hegele et 
al., 2012; Varjosalo et al., 2013).  Taken together, these findings raise the question of whether 
ARGLU1 can regulate the splicing of other RNAs when overexpressed. 
ARGLU1 protein has been shown to interact with MED1, a component of the mediator 
complex to potentiate a transcriptional and cellular response to estrogen in this context (Zhang et 
al., 2011).  Mediator is a large, multi-subunit complex that brings together transcription factors 
and the core RNA pol II machinery, allowing for licensing of transcription.  MED1 in particular 
is known to be recruited to enhancer sequences bound by nuclear receptors and potentiate 
transcriptional activation of regulated genes.  This suggests an alternative role for ARGLU1 in 
transcriptional regulation. 
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In this chapter I will address the role of ARGLU1 protein in regulating transcription levels 
and alternative splicing in a transcriptome-wide manner.  Based on the two probable functions for 
ARGLU1 suggested by previous studies, transcriptional regulation and the splicing machinery, it 
seems likely that ARGLU1 will play a role in RNA transcription or processing. 
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4.2 Results 
4.2.1 RNA-Seq  
To assess the role of ARGLU1 protein overexpression on the transcriptome of HEK 293 
cells, I employed a previously described system to induce the overexpression of ARGLU1 in 
response to tetracycline.  This system uses a tetracycline repressor to inhibit transcription of an 
ARGLU1 cDNA, which is released with the addition of tetracycline.  Therefore, this system could 
be used to compare the mRNA compliment from cells overexpressing ARGLU1 against isogenic 
cells that had not been induced.  Furthermore, to control for the effect of tetracycline, I created cell 
lines to express chloramphenicol acetyltransferase (CAT) following addition of tetracycline. 
There are multiple control samples in this experimental setup.  The main comparisons will 
be made against the ARGLU1 +Tet group, which is the ARGLU1 inducible cell line treated with 
tetracycline, which serves as the main control.  The other control groups at the CAT +Tet group 
and the CAT –Tet, which are the CAT inducible cell line treated with or without tetracycline, 
respectively.  In order to determine differences attributable to overexpression of ARGLU1, rather 
than tetracycline or CAT expression, I have required that differences recovered from informatics 
analysis are significant in either all three control samples compared with ARGLU1 +Tet, or at least 
significantly different in both the CAT +Tet and ARGLU1 –Tet groups. 
I used two different conditions treatment conditions for both the ARGLU1 and CAT 
inducible cell lines.  In duplicate for each condition, cells were treated with 1 µg/mL tetracycline, 
or mock treated, for 24 hours.  During cell harvesting, half the cells were used to create a whole 
cell protein lysate, and the other half were treated with Trizol and processed using the Trulink 
RNA mini kit to extract RNA for RNA-seq and other experiments.  The protein extracts were used 
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to assess the expression level of ARGLU1 in all samples (Figure 4.1).  RNA from each sample 
was analyzed by the Tapestation instrument using the RNA Screentape (Figure 4.2A).  After 
confirming that the RNA Integrity Number equivalent (RINe) (Schroeder et al., 2006) indicated 
the RNA was of high quality, it was used to generate a stranded cDNA library appropriate for 
sequencing on an Illumina platform using the Illumina Stranded mRNA TruSeq protocol.  The 
libraries were run on a high sensitivity DNA screentape (Figure 4.2B) to determine the average 
size distribution of the libraries for molarity calculations, and as a check for aberrant products 
following PCR amplification.  These libraries were then sequenced with 2x76 bp reads on the 
Illumina NextSeq platform. 
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Figure 4.1 Western blot of cell extracts from the cells used for RNA-seq experiments. 
Western blotting was carried out on whole cell extracts from the samples used for RNA-Seq.  
Tubulin was used as a loading control.  The cell lines are indicated at the bottom, and treatment 
with 1 ug/mL tetracycline or mock treatment is indicated below the individual samples. 
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Figure 4.2 Quality control steps for RNA integrity and library size for RNA-seq libraries. 
A. RNA Screentape gel image showing the ribosomal RNA bands from the RNA used for library 
preparation.  The RINe number, and indicator of RNA integrity, is shown at the bottom of the gel 
image.  B. High Sensitivity DNA Screentape image of the RNA-seq libraries. The cell lines are 
indicated at the bottom, and treatment with 1 µg/mL tetracycline or mock treatment is indicated 
below the individual samples.  
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4.2.2 Alignment of RNA-Seq Data 
TopHat2 (Kim et al., 2013) was used to align FASTQ files derived from RNA-Seq raw 
data to the hg19 human reference genome.  Alignment statistics for the 8 individual samples are 
presented in Table 4.1.  All samples showed a high rate of alignment to the human reference 
genome (See table 4.1).  The output of Tophat2 is a .BAM file, which can be displayed graphically 
as alignments on the human genome.  Furthermore, there .BAM files can be used to make a 
coverage track, which sums the number of reads aligning to a given base in the reference genome.  
These genome coverage tracks can be accessed through the UCSC genome browser.  
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Sample 
ARGL
U1 – 
Tet 
Rep 1 
ARGL
U1 - 
Tet 
Rep 2 
ARGL
U1 
+Tet 
Rep 1 
ARGL
U1 
+Tet 
Rep 2 
CAT -
Tet 
Rep 1 
CAT -
Tet 
Rep 2 
CAT 
+Tet 
Rep 1 
CAT 
+Tet 
Rep 2 
Left Reads 
total 
4.41E+
07 
7.07E+
07 
4.36E+
07 
4.37E+
07 
3.51E+
07 
5.16E+
07 
4.36E+
07 
4.07E+
07 
Left reads 
mapped 
3.84E+
07 
6.12E+
07 
3.72E+
07 
3.80E+
07 
3.04E+
07 
4.52E+
07 
3.78E+
07 
3.56E+
07 
% of input 87.00% 86.58% 85.24% 86.91% 86.83% 87.53% 86.73% 87.50% 
Left 
multiple 
alignment 
4.30E+
06 
7.35E+
06 
4.69E+
06 
4.59E+
06 
3.34E+
06 
5.50E+
06 
4.46E+
06 
4.13E+
06 
% multiple 
alignment 
11.21% 12.02% 12.61% 12.09% 10.96% 12.17% 11.80% 11.60% 
Right reads 
total 
4.41E+
07 
7.07E+
07 
4.36E+
07 
4.37E+
07 
3.51E+
07 
5.16E+
07 
4.36E+
07 
4.07E+
07 
Right Reads 
Mapped 
3.81E+
07 
6.07E+
07 
3.69E+
07 
3.77E+
07 
3.02E+
07 
4.49E+
07 
3.76E+
07 
3.53E+
07 
% of input 86.36% 85.95% 84.65% 86.26% 86.10% 86.96% 86.17% 86.73% 
Right 
multiple 
alignments 
4.38E+
06 
7.45E+
06 
4.75E+
06 
4.65E+
06 
3.39E+
06 
5.60E+
06 
4.53E+
06 
4.20E+
06 
% multiple 
alignment 
11.49% 14.27% 12.87% 12.34% 11.23% 12.47% 12.05% 11.89% 
Aligned 
Pairs 
3.74E+
07 
5.97E+
07 
3.63E+
07 
3.71E+
07 
2.97E+
07 
4.41E+
07 
3.69E+
07 
3.47E+
07 
Paired 
Multiple 
Alignments 
3.17E+
06 
5.44E+
06 
3.51E+
06 
3.43E+
06 
2.45E+
06 
4.08E+
06 
3.33E+
06 
3.05E+
06 
Discordant 
Aligned 
Pairs 
3.52E+
05 
5.96E+
05 
3.94E+
05 
3.80E+
05 
2.79E+
05 
4.45E+
05 
3.69E+
05 
3.30E+
05 
% 
Concordant 
Pair 
Alignment 
84.09% 83.61% 84.24% 83.96% 83.85% 84.52% 83.77% 84.45% 
Table 4.1 Alignment statistics for the 8 samples sequenced.  
 
 
83 
 
4.2.3 Overexpression of ARGLU1 alters the abundance of a number of genes 
I utilized the RNA-seq statistical package Cuffdiff (Trapnell et al., 2013), which is 
incorporated in the Cufflinks suite of RNA-seq analysis tools (Trapnell et al., 2010), to 
quantitatively compare the alignments derived from TopHat on a gene and isoform level.  Cuffdiff 
generates uses a measure known as Fragments Per Kilobase of transcript per Million reads mapped 
(FPKM), which allows for comparisons of transcript levels between samples.  Based on the 
Cuffdiff output, 16 genes were significantly upregulated in the ARGLU1 +Tet group compared 
with all three control groups.  A further 8 genes were upregulated in the ARGLU1 +Tet group 
compared with the CAT +Tet and ARGLU1 –Tet groups.  There were substantially more genes 
downregulated following ARGLU1 overexpression, with 107 genes downregulated following in 
the ARGLU1 +Tet group compared with all three control groups, and 54 genes downregulated 
compared with the CAT +Tet and ARGLU1 –Tet groups.  These genes are listed in Table 4.2. 
To determine if there was any enrichment of genes with similar molecular function, I used 
the list of up- and downregulated genes to query the DAVID functional annotation tool (Table 
4.3).  I found that the most highly enriched molecular function was catalytic activity, indicating 
that ARGLU1 seems to be regulating the expression levels of enzymes.  Two other enriched 
molecular functions were the categories lyase and hydrolase. 
To validate the Cuffdiff findings of genes that were upregulated and downregulated, I 
performed semi-quantitative RT-PCR for selected.  I found that when RT-PCR was performed on 
duplicate samples from ARGLU1 –Tet and ARGLU1 +Tet cells, these RT-PCR reactions followed 
the trends observed in by Cuffdiff analysis (Figure 4.3A and B).  Interestingly, two genes involved 
in paraspeckles, PSPC1 and the lncRNA NEAT1, were both downregulated upon ARGLU1 
overexpression (Figure 4.3B)  
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Upregulated Significantly in ARGLU1 +Tet compared to 
3 groups 
Upregulated in ARGLU1 
+Tet compared to both CAT 
+Tet and ARGLU1 -Tet 
ABHD16A BTN3A3 DDX39A RIMKLB CMTR2 TCP10L 
ARGLU1 C21orf140 FBXL5 SNRPA1 COQ2 ZNF117 
ATF7IP2 CCNH N6AMT1 SRSF2 MOSPD2 ZNF223 
BTN3A2 CHPF2 OVGP1 TNFRSF10D NAPB ZSCAN12P1 
      
Downregulated Significantly in ARGLU1 +Tet 
compared to 3 groups 
Downregulated in ARGLU1 
+Tet compared to both CAT 
+Tet and ARGLU1 -Tet 
ABHD14B FAM86B1 MIR4435-1HG SAT1 ABCA2 MXRA8 
ACYP1 FAM86FP MPC1 SERPINB1 ABHD16B NAGLU 
AIG1 FAM86HP MRPL1 SFXN2 ATHL1 NAT14 
ANKRD29 FBXL4 NEAT1 SHISA4 C17orf70 NDUFV3 
AP1S2 GALT NIPSNAP3A SIGMAR1 C1QTNF6 NPTXR 
APTX GATS NPL SLC35G1 CBS NUDT18 
ASB16-AS1 GDAP1 NRBP2 SLC5A3 CCNL2 NUDT8 
ASIC1 GNE PCYOX1L SMARCD3 CENPM OCEL1 
ATP5G1 H6PD PEX7 STYXL1 CYB5D2 PAPLN 
ATP7B HAGHL PIGV TCTA D2HGDH PCBP4 
ATPAF2 HDHD2 PIGX TCTN1 DNPH1 PCK2 
C22orf29 HGSNAT PM20D2 TDRP DPYSL4 PHF7 
C22orf39 HMGCL PPCDC THBS3 FAM132B PIGQ 
CBR4 HOXC-AS1 PPCS THSD4 GALNT16 PPM1M 
CCDC53 HSD17B8 PPFIA4 TMCC1-AS1 HINT2 PYCRL 
CDHR1 IFT88 PPM1N TMEM187 IDH2 RPUSD3 
CLN5 IGDCC4 PPP1R21 TUSC3 IL17RC SEMA6C 
COL4A4 LINC00152 PRAF2 TXNRD3 KIAA0141 SH3GLB2 
COL4A5 LINC00173 PRELID2 TYSND1 LOC100129534 SPATA20 
DDIT4 LINC01004 PSPC1 UCP2 LOC101927667 SPC24 
DDT LINC01184 RBM3 UNC119B LTBP4 ST3GAL3 
DENND5B LINC01355 RBPMS2 UNK MAPK11 TMEM219 
DHRS11 LYRM1 RHBDD2 UQCC2 MAPK12 TMEM42 
DOK3 LYRM9 RNF216P1 UROS MC1R TPCN1 
EMC3-AS1 LZTS3 RRAGB WDR31 MFSD3 TRAPPC6A 
EPHX1 METTL21B RRM2 WEE1 MMP24-AS1 TTC38 
EPHX2 MGC72080 RWDD2B  MORN1 ZNF586 
Table 4.2 Genes significantly upregulated and downregulated in ARGLU1 +Tet group 
compared to controls. 
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Category Term Count 
P 
Value 
Fold 
Enrichment 
Benjamini FDR Genes 
Molecular 
Function 
catalytic 
activity 
67 1.83E-08 1.77E+00 5.90E-06 
2.48E
-05 
HGSNAT, SAT1, SPATA20, 
D2HGDH, TUSC3, LTBP4, 
HINT2, PPCS, CHPF2, N6AMT1, 
ST3GAL3, MC1R, ACYP1, 
HMGCL, NUDT18, PCYOX1L, 
CCNH, RPUSD3, PIGV, APTX, 
CBR4, SIGMAR1, PIGQ, WEE1, 
COQ2, H6PD, RRM2, TYSND1, 
DDT, FBXL5, TXNRD3, PPM1N, 
HAGHL, PPM1M, NRBP2, 
PYCRL, STYXL1, NAGLU, GNE, 
UROS, ATHL1, ABCA2, 
ATP5G1, PPCDC, NUDT8, IDH2, 
NAT14, HSD17B8, OVGP1, 
PM20D2, DHRS11, NPL, GALT, 
EPHX2, EPHX1, DPYSL4, 
ABHD14B, PAPLN, MAPK11, 
PCK2, RIMKLB, NDUFV3, 
MAPK12, THSD4, HDHD2, 
ATP7B, CBS 
Molecular 
Function 
carbon-
carbon 
lyase 
activity 
5 2.30E-04 1.64E+01 3.64E-02 
3.11E
-01 
DDT, NPL, PPCDC, PCK2, 
HMGCL 
Molecular 
Function 
lyase 
activity 
7 7.75E-04 6.38E+00 7.99E-02 
1.04E
+00 
DDT, NPL, UROS, PPCDC, 
PCK2, HMGCL, CBS 
Molecular 
Function 
manganese 
ion binding 
7 8.59E-04 6.26E+00 6.68E-02 
1.15E
+00 
NUDT18, NUDT8, PPM1N, IDH2, 
PPM1M, PCK2, RIMKLB 
Molecular 
Function 
cofactor 
binding 
7 0.00922 3.87E+00 4.49E-01 
1.18E
+01 
D2HGDH, TXNRD3, UROS, 
IDH2, CBR4, HMGCL, CBS 
Molecular 
Function 
hydrolase 
activity 
27 0.0102 1.63E+00 4.26E-01 
1.30E
+01 
STYXL1, NAGLU, HINT2, 
ATHL1, ABCA2, ATP5G1, 
MC1R, NUDT8, ACYP1, 
NUDT18, OVGP1, CCNH, 
PM20D2, EPHX2, DPYSL4, 
APTX, EPHX1, PAPLN, 
ABHD14B, H6PD, TYSND1, 
THSD4, PPM1N, HDHD2, 
HAGHL, PPM1M, ATP7B 
Molecular 
Function 
magnesium 
ion binding 
9 0.0163 2.74E+00 5.31E-01 
2.00E
+01 
NUDT18, MAPK12, NUDT8, 
EPHX2, PPM1N, IDH2, PPM1M, 
WEE1, ATP7B 
Molecular 
Function 
oxidoreduct
ase activity 
11 0.0266 4.20E+00 6.63E-01 
3.06E
+01 
NDUFV3, PYCRL, D2HGDH, 
PCYOX1L, H6PD, RRM2, 
DHRS11, TXNRD3, IDH2, CBR4, 
HSD17B8 
Molecular 
Function 
coenzyme 
binding 
5 0.0417 3.80E+00 7.83E-01 
4.38E
+01 
D2HGDH, TXNRD3, IDH2, 
CBR4, HMGCL 
Molecular 
Function 
transferase 
activity 
19 0.0754 1.49E+00 9.20E-01 
6.53E
+01 
SAT1, HGSNAT, TUSC3, GNE, 
CCNH, LTBP4, HINT2, PIGV, 
GALT, MAPK11, CHPF2, PIGQ, 
WEE1, N6AMT1, ST3GAL3, 
COQ2, MAPK12, NAT14, NRBP2 
Table 4.3 Molecular Function GO analysis of genes significantly upregulated and 
downregulated following ARGLU1 overexpression. 
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Figure 4.3 Semi-Quantitative RT-PCR confirms upregulated and downregulated genes 
following ARGLU1 overexpression.  A.  RT-PCR was performed for the indicated genes.  B. 
RT-PCR was performed for the paraspeckle components PSPC1 and NEAT1. For all samples, 
lanes 1 and 2 are duplicate samples from mock treated ARGLU1-TO cells, while lanes 3 and 4 
are duplicate samples from ARGLU1-TO cells treated with 1 ug/mL tetracycline.  
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4.2.4 Overexpression of ARGLU1 causes alternative splicing of a number of genes 
Besides assessing gene level differences in expression, Cuffdiff is also able to create 
expression profiles for individual isoforms of expressed genes, thus allowing for an analysis of 
alternative splicing.  To this end, I queried the differential splicing Cuffdiff output for genes that 
were significantly alternatively spliced.  I have summarized these findings in Table 4.4.  Notably 
this is a much smaller list.  This may be explained by the fact that each group only contained two 
replicates.  Cuffdiff generally requires three replicates for each group to make alternative splicing 
predictions.  This program may not be able to generate robust alternative splicing results with only 
two replicates.  Furthermore, there were many more alternative splicing events that were annotated 
between ARGLU1 +Tet and the CAT +/- Tet samples that may not have risen to the level of 
significance in the ARLGU1 –Tet sample because only two samples were used, or because there 
was some basal ARGLU1 expression in the absence of tetracycline that confounded these results. 
I used the alternatively spliced Cuffdiff output to query the DAVID functional annotation 
tool to determine enrichment in molecular function (Table 4.5).  Notable molecular functions 
included oxoreductase activity, cation binding, and cytoskeletal components. 
In order to validate the alternative splicing predicted, I performed RT-PCR using primers 
that would include the alternative splicing event by crossing multiple exons, including alternative 
exons.  RT-PCR indicated that alternative splicing found in the selected genes could be replicated 
using an alternative measure (Figure 4.4). 
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Significantly Alternatively Spliced in ARGLU1 +Tet 
compared to 3 control groups  
Significantly Alternatively 
Spliced in ARGLU1 +Tet 
compared to both CAT +Tet 
and ARGLU1 -Tet 
AK2 FGFR2 NFATC1 
SERPINB
1 
ADD3 ITPR1 SYTL5 
BAG6 GPR98 NIN SLC25A1 AGER 
LAMTOR
3 
UBE2Q2 
BUB3 HIBCH NUDT7 STAG2 ALOX5 PCDH7 ZNF430 
C8orf59 IL17RC P4HA2 TCF19 AOC3 PMS1 ZNF438 
CDC42EP
3 
KDM6A PAX6 TUSC3 
BTN3A
3 
RASSF7 
FAM63
A 
CEP131 KIAA0319 
PPARGC1
B 
UNK CA12 RPH3AL NUDT7 
DEPDC1 MIS12 PRMT2 URI1 
INCEN
P 
SLC26A6 PLCB3 
DPH3 MORF4L2 RALGPS2 YIPF1    
DTNA 
MRPS6,SLC5A
3 
RFC5 ZNF207    
EPB41L4
B 
MYO1B RFX3 ZXDC    
ETV1 NDUFV3 SAMD4A     
Table 4.4 Genes found to be significantly alternatively spliced in the ARGLU1 +Tet group.  
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Category Term Count 
P 
Value 
Fold 
Enrichment 
Benjamini FDR Genes 
Molecular 
Function 
oxidoreductase 
activity, acting on 
single donors with 
incorporation of 
molecular oxygen 
3 0.0254 1.19E+01 9.08E-01 27.27 KDM6A, P4HA2, ALOX5 
Molecular 
Function 
metal ion binding 23 0.0298 1.47E+00 8.45E-01 31.22 
SLC5A3, KDM6A, ZNF430, 
CA12, ZXDC, RPH3AL, DPH3, 
PCDH7, ITPR1, GPR98, 
ZNF207, SLC26A6, PLCB3, 
P4HA2, NUDT7, SYTL5, 
TCF19, UNK, ALOX5, ZNF438, 
ADD3, DTNA, AOC3 
Molecular 
Function 
cation binding 23 0.0331 1.46E+00 7.89E-01 34.03 
SLC5A3, KDM6A, ZNF430, 
CA12, ZXDC, RPH3AL, DPH3, 
PCDH7, ITPR1, GPR98, 
ZNF207, SLC26A6, PLCB3, 
P4HA2, NUDT7, SYTL5, 
TCF19, UNK, ALOX5, ZNF438, 
ADD3, DTNA, AOC3 
Molecular 
Function 
cytoskeletal protein 
binding 
6 0.0376 3.15E+00 7.58E-01 37.75 
MYO1B, RPH3AL, EPB41L4B, 
ADD3, CDC42EP3, GPR98 
Molecular 
Function 
ion binding 23 0.0388 1.44E+00 7.05E-01 38.73 
SLC5A3, KDM6A, ZNF430, 
CA12, ZXDC, RPH3AL, DPH3, 
PCDH7, ITPR1, GPR98, 
ZNF207, SLC26A6, PLCB3, 
P4HA2, NUDT7, SYTL5, 
TCF19, UNK, ALOX5, ZNF438, 
ADD3, DTNA, AOC3 
Molecular 
Function 
calcium ion binding 8 0.0506 2.31E+00 7.46E-01 47.39 
SLC26A6, PLCB3, PCDH7, 
ALOX5, ITPR1, GPR98, DTNA, 
AOC3 
Molecular 
Function 
transition metal ion 
binding 
16 0.0736 1.52E+00 8.29E-01 61.15 
KDM6A, ZNF430, CA12, 
ZXDC, RPH3AL, DPH3, 
ZNF207, P4HA2, NUDT7, 
SYTL5, TCF19, ALOX5, UNK, 
ZNF438, DTNA, AOC3 
Table 4.5 Molecular function Gene Ontology of genes with significant alternative splicing 
following ARGLU1 overexpression. 
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Figure 4.4 Validation of alternative splicing following ARGLU1 overexpression.  A. Splicing 
sensitive RT-PCR for the c8orf59 transcript.  B.  Splicing sensitive RT-PCR for MORF4L2.  C. 
Splicing sensitive RT-PCR for ACYP1.  D. Splicing sensitive RT-PCR for URI.  For all 
experiments, lanes 1 and 2 are duplicate samples from mock treated ARGLU1-TO cells, while 
lanes 3 and 4 are duplicate samples from ARGLU1-TO cells treated with 1 ug/mL tetracycline.  
For all tested events, the UCSC browser track for this alternative splicing event as well as a cartoon 
depiction of the alternative splicing event is noted.  Primers are indicated by black arrows beneath 
the cartoon.  
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4.3 Conclusion 
 In this chapter I have assessed the transcriptome-wide effect of ARGLU1 overexpression.  
I found that a number of genes are upregulated and downregulated following inducible 
overexpression of ARGLU1.  These genes are enriched for Gene Ontology categories including 
catalytic activity and ion binding.  Furthermore, a number of genes were found to be alternatively 
spliced by Cuffdiff analysis, despite technical shortcomings resulting from the use of two RNA-
seq replicates per group rather than three.  I was able to validate the findings from RNA-Seq for a 
number of genes using RT-PCR to assess both expression level as well as alternative splicing. 
 Overexpression may not represent the ideal condition for assessing transcriptional and 
splicing events regulated by ARGLU1.  A better system may be to look at cells in which ARGLU1 
has been knocked out.  I will address methods to generate these results in the next chapter. 
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4.4 Materials and Methods 
Cell Culture 
HEK 293-Flp-In TRex cells were maintained in DMEM with 10% FBS and 100 U/mL Penicillin-
Streptomycin.  Cells in which the pcDNA5/FRT vector had been integrated were additionally 
maintained in media supplemented with Blastcidin and Hygromycin B.  Induction of protein 
expression was performed by supplementing DMEM/Blast/Hygromycin media with 1 ug/mL 
tetracycline. 
Western blotting 
Cells were lysed for 30 minutes in ice cold RIPA buffer supplemented with protease inhibitors and 
benzonase.  Protein was quantified using the BioRad Cell lysates were then mixed with 2X 
Laemmli’s SDS loading buffer with 10 mM DTT.  30 µg of protein was loaded into SDS-PAGE 
gels and resolved at 100V.  Transfer to nitrocellulose membrane was carried out in Tris-glycine 
buffer with 10% methanol at 4°C at 240 mA for 2 hour.  Membranes were blocked with Licor 
blocking buffer for 1 hr at room temperature.  Blots were then incubated overnight at 4°C with 
primary antibody diluted in Licor blocking buffer supplemented with 0.1% tween-20.  Membrane 
was then washed with TBS-0.1% tween 3 times for five minutes. Appropriate florescent labeled 
secondary antibodies diluted in Licor blocking buffer with 0.1% tween and 0.01% SDS were 
incubated with the membrane for 45 minutes at room temperature with rocking.  Membrane was 
then washed with TBS-0.1% tween 3 times for five minutes.  Membranes were imaged on the 
Licor Odyssey system. 
Preparation of RNA 
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RNA was prepared by lysing cells in an appropriate volume of Trizol (Life Tech).  Chloroform 
was added, mixed vigorously, and incubated on ice for 5 minutes.  These samples were centrifuged 
at maximum speed for 15 minutes.  The aqueous phase was then mixed with 70% ethanol and 
processed with the Purelink RNA mini kit according to the manufacturer’s instructions.  RNAs 
were treated with Purelink On-column DNase I.  RNA concentration was assessed using 
Absorbance at 280 on a nanodrop spectrophotometer.  1 uL of RNA for library preparation was 
run on the RNA Screentape on the tapestation machine. 
RNA-Seq library generation 
RNA was prepared for sequencing using the TruSeq Stranded mRNA Library Prep Kit from 
Illumina according to the manufacturer’s direction.  Briefly, poly(A) mRNA was selected with 
two rounds of oligo-d(T) selection.  RNA was then fragmented, and reverse transcription was 
carried out using random primers. Second strand synthesis was then carried out, with dUTP in 
place of dTTP.  The ds-cDNA was then end repaired and A-tailed.  Adaptors were then ligated.  
Each sample was tagged with a unique barcode.  Finally, libraries were amplified with 15 cycles 
of PCR and purified away from the primers using Axyprep PCR cleanup kit (Axygen).  The final 
libraries were then quantified using Qubit 2.0 high sensitivity (Life Technologies).  1 uL of each 
library was also run on the Tapestation instrument using a high sensitivity DNA Screentape 
(Agilent).  These results were used to calculate the molarity of the libraries.  Sequencing libraries 
were diluted to 2 nM and pooled.  PhiX sequencing library was added at 5% of the pooled libraries.  
Finally, the pooled library was prepared for sequencing on the NextSeq 500 using a 150 cycle high 
output flow cell, with 2x76 read length. 
Alignment 
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After sequencing was complete, FASTQ files were generated and concatenated for each sample.  
FASTQs were then aligned with the hg19 Human Genome Reference from UCSC using Tophat 2 
to output genomic alignments in the form of .bam files.  Accepted_hits.bam file for each sample 
were then sorted using the samtools sort command, and indexed using the samtools index 
command.  These .bam files were then turned into genome coverage tracks using the bedtools 
command genomeCoverageBed -bg -split –ibam.  This genome coverage track was then used to 
make a BigWig track with the command bedGraphToBigWig.  These files were then used for 
display on the UCSC genome browser. 
Cuffdiff analysis 
I ran Cuffdiff with the following command options: 
cuffdiff -min-reps-for-js-test 1-L C_min,C_plus,A_min,A_plus -p 24 -library-type fr-firststrand  
using the UCSC_hg19 genes.gtf file as a reference, which was obtained from the Tophat2 website 
at https://ccb.jhu.edu/software/tophat/igenomes.shtml, accessed on  30 November, 2014.
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Chapter 5 
Discussion and Future Directions 
5.1 Discussion 
 In this dissertation, I have addressed a number of questions regarding the regulation and 
regulatory function of the protein ARGLU1.  The first question I addressed is the role of an 
ultraconserved element (UCE) in the complex alternative splicing of ARGLU1 mRNA.  These 
experiments demonstrated that the ARGLU1 UCE is necessary and sufficient to induce intron 
retention and inhibition of splicing.  I next addressed the question of whether ARGLU1 protein 
can regulate alternative splicing of its own mRNA.  Indeed, overexpression of ARGLU1 causes a 
rapid and dramatic shift in the splicing of endogenous ARGLU1 mRNA.  Finally, using RNA-Seq, 
I asked whether ARGLU1 protein can cause changes in splicing of other genes.  I will now discuss 
each of these findings to put them in the context of previous reports. 
5.1.1 Cis-Element control of alternative splicing 
Since alternative splicing was first described in the early 1980s (Alt et al., 1980; Early et 
al., 1980), there have been efforts to understand the regulatory elements present within RNA 
transcripts themselves that direct alternative splicing , and were known to interact with trans-
factors.  As described earlier, these splicing regulatory elements (SREs) can be found in both 
introns and exons, and can both enhance and suppress splicing (Braunschweig et al., 2013; Fu and 
Ares, 2014; Wang and Burge, 2008). 
In ARGLU1 alternative splicing, the cis-elements contained in the UCE seem to have a dual 
role.  One function is to suppress inclusion of the alternative exon.  These elements are located 
downstream of the alternative exon.  The evidence for this is found in experiments in which three 
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25 bp deletion were made downstream of the alternative exon that increased the inclusion of the 
alternative exon.  Interestingly, these deletions also caused usage of 5’-splice sites other than the 
annotated site for the alternative exon.  Furthermore, mutation of GU dinucleotides (specifically 
SS5 and SS6) downstream of the alternative exon caused a dramatic increase in splicing of exons 
2 and 3.  Therefore, there are a number of sequences in the downstream region that are acting as 
intronic splicing silencers. 
One model that I proposed for the inhibition of splicing between ARGLU1 exon 2-3 is the 
presence of multiple competing 5’-splice sites following the alternative exon.  It has been shown 
that multiple 5’-splice sites, each engaged with U1 can cause inefficient recognition of the true 5’-
splice site and prevent the splicing reaction from proceeding past the E complex (Roca et al., 2013; 
Sharma et al., 2005).  Therefore, it is possible that the alternative exon is able to undergo exon 
definition, but the presence of multiple 5’-splice sites interacting with the 3’-splice site of exon 3 
causes stalling of the splicing reaction, which, if not resolved results in intron retention. 
Another model, which is not mutually exclusive with the first model, is that the alternative 
exon has very poor splice sites, which can engage with the splice sites of the upstream and 
downstream exons, but result in an abortive splicing reaction, possibly because of the competition 
for 5’-splice sites proposed in model 1.  There is certainly evidence that the alternative exon splice 
sites are weak, as mutation of these splice sites individually caused exclusive splicing to the 
alternative exon.  Weak splice sites have been observed to be a common phenomenon in 
alternatively spliced exons, as it allows for regulation through the interaction between cis-
regulatory elements and trans-regulatory factors (Sakabe and de Souza, 2007; Zhan, 2013).  The 
possible regulatory role of trans-acting factors will be discussed in the next section. 
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5.1.2 ARGLU1 regulates its own alternative splicing—A new splicing trans-regulatory 
element? 
In Chapter 3, I presented evidence that overexpression of an ARGLU1 cDNA caused a 
dramatic and rapid shift in the splicing of ARGLU1 mRNA away from exon 2-3 splicing toward 
increased intron retention as well as increased inclusion of the alternative exon.  Furthermore, 
treatment with the translation inhibitor emetine caused an increase in the level of ARGLU1 spliced 
isoform that correlated with a decrease in ARGLU1 protein levels.  An additional insight into the 
emetine treatment experiments is that under translational inhibition, levels of mRNA including the 
alternative exon were increased, indicating that this transcript is most likely degraded by the 
nonsense mediated decay pathway (NMD), as predicted. 
Interestingly, very similar alternative splicing regulation has been seen in a number of 
splicing factors, and are often associated with ultraconserved elements (Baek and Green, 2005; 
Lareau et al., 2007; Ni et al., 2007; Sun et al., 2010; Sureau et al., 2001).  Indeed, experiments very 
similar to those I performed, in which SRSF1 (SF2/ASF) (Sun et al., 2010) or SRSF2 (SC35) 
(Sureau et al., 2001) were overexpressed under exogenous control, found that these splicing factors 
caused increased usage of alternative exons that induced NMD.  Furthermore, SRSF1 has a number 
of retained intron isoforms that are localized in the nucleus (Boutz et al., 2015; Sun et al., 2010). 
 The exact mechanism of ARGLU1 autoregulation is not clear from our experiments.  
However, I will suggest a number of different models.  First, ARGLU1 may bind directly to 
sequences within the UCE or the flanking exons and cause a decrease in exon 2-3 spicing.  This 
could be caused by increased inhibition of this splicing event, or it could be the result of increased 
exon 2-alt exon-exon 3 splicing.  In chapter 3 I presented evidence that overexpression of 
ARGLU1 protein causes increased splicing inclusion of the alternative exon which targeted it for 
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NMD, however it is unclear exactly how much this splicing contributes to regulation of exon 2-
exon 3 splicing. 
A second possible mechanism is that ARGLU1 is interacting with another splicing factor 
to mediate alternative splicing.  Multiple efforts to define the full complement of mRNA proteins 
have not identified ARGLU1 as an RNA binding protein (Baltz et al., 2012; Castello et al., 2012).  
It is known that the RS domains of SR proteins interact with other non-SR proteins, such as U1-
70K, through their own RS domains (Wu and Maniatis, 1993).  As I have shown in chapter 1, 
ARGLU1 also contains an N-terminal domain multiple groups of SR dipeptides.  Thus it is not 
unreasonable to assume that ARGLU1 can interact with SR proteins as well as other proteins with 
RS domains.  In the context of ARGLU1 overexpression, this could have two effects.  First, it 
could allow for increased ARGLU1 recruitment to the RNA, possibly mediating further 
interactions.  Alternatively, it could interact with SR proteins or some other splicing regulator, 
causing them to be removed from the RNA, thus squelching their function and altering splicing. 
Either of these possible mechanisms can be extended to the transcriptome wide splicing 
effects we observed in chapter 4.  The small group of genes that were seen to be alternatively 
spliced in chapter 4 may suggest that ARGLU1’s function is not on splicing.  However, the analysis 
of alternative splicing by Cuffdiff may have been somewhat limited by only having two 
sequencing replicates while the Cuffdiff literature recommends three.  Below, I will suggest a 
number of experiments that should help clarify the mechanism of ARGLU1 alternative splicing 
regulation and its larger cellular role. 
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5.2 Future Directions 
Based on the findings presented in this dissertation and the reports of others, I suggest that 
ARGLU1 is a new SR-like protein that plays a role in alternative splicing.  To further understand 
the role that ARGLU1 plays in this process, I have described a number of lines of inquiry that 
should be fruitful. 
5.2.1 Knock out the UCE in an animal model 
In this study I have presented evidence that the UCE located in intron 2 is important for 
regulation of complex alternative splicing of ARGLU1¸ including the intron retention phenotype 
as well as the inclusion of the alternative exon.  The high level of sequence conservation, and the 
demonstrated function of this sequence suggests that this regulation is quite important, and has 
been under selective pressure through evolutionary time.  Strikingly, these two alternative splicing 
events seem to be conserved in other species, and most likely play a similar role.  To address the 
function of this UCE at an organismal level, a conditional or global knock out of the UCE sequence 
in an animal model such as the mouse or even Xenopus would be of great interest to provide insight 
into the evolutionary selective pressure that has preserved this sequence.  Alternately, this could 
be accomplished by the knock-in of a construct missing the UCE.  Recent advances in genome 
editing techniques, such as Cas9/CRISPR, should make generation of this mouse line fast and 
efficient. 
5.2.2 Knock out ARGLU1 in an animal model or cell line 
As a complimentary experiment it will be of interest to examine the knock out mouse of 
ARGLU1 protein.  The International Mouse Phenotyping Consortium has generated a number of 
constructs that would be of great use for understanding the expression of ARGLU1 as well as its 
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cellular and development role.  These knockouts exist as ES cells that can be used different ways.  
The knock-out scheme used provides the ability to use LacZ as a gene trap to assess the distribution 
of expression as well as the conditional knock-out potential.  This would provide a useful tool for 
understanding the developmental and tissue specific role that ARGLU1 plays, as well as answering 
the question of whether ARGLU1 is important for cellular viability or animal development.  
Furthermore, the presence of a floxed allele in an ES cell line would allow for the introduction of 
knock-in alleles, including the knock-in of a construct missing the UCE, as discussed previously.  
Finally, this could allow for the production of ARGLU1 knock-out cell lines, which could be useful 
for performing experiments such as RNA-seq by directly comparing identical cell types. 
Instead of using a mouse system to knock out ARGLU1, another tractable method would 
be to use the Cas9/CRISPR technology discussed previously to induce targeted double-stranded 
breaks, which will then be repaired by non-homologous end joining to cause insertions and 
deletions, causing a knock out of the gene.  These cell lines could then be used to assess the 
functional role of ARLGU1.  One key experiment that should be performed with ARGLU1 cell 
knockouts is RNA-seq.  Often, decreased expression of proteins is much more informative than 
overexpression, especially if the protein is already fairly highly expressed.  Additionally, RNA-
Seq from a knock-out cell line would allow for a comparison to RNA-Seq results from the 
ARGLU1 over-expressing cells.  I am currently screening cells transduced with lentivirus 
expressing cas9 that can be selected with puromycin along with a number of sgRNAs targeting the 
first and second exon of ARGLU1.  I am hoping to find cells in which the ARGLU1 protein is not 
expressed.  These cells can then be used for further experiments to test the cellular response to the 
lack of ARGLU1, such as analysis of ARGLU1 mRNA splicing or global changes in mRNA 
expression and splicing. 
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5.2.3 Experiments using the inducible ARGLU1 system 
I have generated a number of resources that will be useful for further experiments to 
understand the role of ARGLU1.  First, I have generated cell lines that allow for inducible 
expression of ARGLU1, as well as an HA tagged versions of the protein.  This tag allows for the 
specific immunoprecipitation of this protein.  I would suggest that this will be important for a 
number of experiments. 
Deletion of protein domains or mutation of individual amino acids in the inducible ARGLU1 
First, I would suggest a closer interrogation of the ARGLU1 protein domains necessary 
for regulation of its own splicing.  I have already cloned an HA-tagged ARGLU1 cDNA into the 
pcDNA5/FRT/TO plasmid, thus making deletions in the protein and overexpressing them in cells 
should be feasible.  Furthermore, a number of serines in the RS domain of ARGLU1 has been 
shown to be phosphorylated (Varjosalo et al., 2013).  Phosphorylation of the RS domains in SR 
proteins are known to be important for their function and subcellular localization (Aubol et al., 
2013; Cáceres et al., 1997).  Thus mutation of these serines may give some insight into their 
function in ARGLU1. 
RNA-Immunoprecipitation based experiments 
Second, if ARGLU1 is indeed important in splicing, a key experiment will be to determine 
what RNAs ARGLU1 is targeted to.  To accomplish this, it would be useful to perform RIP-seq 
(Townley-Tilson et al., 2006), in which immunoprecipitation of ARGLU1 would be followed by 
preparation of RNA-seq libraries to determine the population of RNAs that are associated with 
ARGLU1.  This experiment should be greatly aided by having an HA tagged protein, as there are 
commercially available anti-HA antibodies that work well for immunoprecipitation.  Possible 
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pitfalls of this approach are that the interaction between ARGLU1 and its targets may be transitory, 
as well as the possibility of non-physiological interactions taking place after cell lysis, leading to 
increased background (Mili and Steitz, 2004).  Another approach to identifying ARGLU1-
interacting RNAs is to use CLIP-seq, in which proteins and RNAs are cross-linked with either UV 
(Licatalosi et al., 2008; Ule et al., 2003), or formaldehyde (Silverman et al., 2014).  Notably, UV 
crosslinking will only create protein-RNA and RNA-RNA crosslinks, and will cause protein-
protein interactions.  If ARGLU1 is not an RNA binding protein but instead functions through 
protein-protein interactions, UV crosslinking will not be a viable method of determining the 
population of bound RNAs. 
Purification of ARGLU1 containing complexes 
A third important use for a system to induce expression of tagged ARGLU1 is to affinity 
purify the proteins that ARGLU1 binds to.  I have carried out initial experiments using a polyclonal 
antibody against ARGLU1, indicating that there is a limited number of proteins bound to 
ARGLU1.  However, a high affinity tag or two-step purification process may represent a better 
system to purify ARGLU1-containing protein complexes.  So far other studies have only 
tangentially tied ARGLU1 to either the mediator complex (Zhang et al., 2011) or the spliceosome 
(Behzadnia et al., 2007; Deckert et al., 2006; Hegele et al., 2012).  Proteomic analysis of ARGLU1 
protein-protein interactions should help resolve the uncertainty about ARGLU1’s molecular 
function.  Other biochemical studies of ARGLU1 will also be helpful in purifying the protein and 
its associated complexes.  For example, use of a protein size exclusion columns or sucrose 
sedimentation, followed by immunoblotting, may further facilitate characterization and 
purification of ARGLU1-containing complexes. 
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I have identified ARGLU1 as regulating the splicing of a number of transcripts, including 
the homeostatic splicing of its own transcript.  However, as alternative splicing is a highly complex 
process, it is highly unlikely that ARGLU1 alone is causing this alternative splicing.  Finding other 
proteins that regulate the splicing may be accomplished by a number of methods.  First, siRNA or 
shRNA mediated knock down of a large number of RNA binding proteins has been a useful tool 
for identifying splicing events regulated by those proteins (Pandit et al., 2013; Park et al., 2004; 
Saltzman et al., 2011).  Indeed, Saltzman et al. knocked down SRSF1 and saw decreased levels of 
alternative exon and increased levels of exon2-exon3 splicing in ARGLU1 mRNA (Saltzman et 
al., 2011 supplmental table 1).  Thus, further high throughput studies of RNA binding proteins 
may provide useful information on proteins regulating alternative splicing of ARGLU1.  A second 
method may be to use RNA from the UCE to identify proteins bound to this region.  I have 
previously carried out preliminary studies using an aptamer tagged version of portions of the 
ARGLU1 UCE to affinity purify proteins bound to this sequence, and identify them using mass 
spectrometry.  However, these results have not yet been functionally validated. 
Fluorescent tagging to identify subcellular localization 
Yet another use of the inducible expression system will be to investigate the subcellular 
localization of ARGLU1.  Previous studies have indicated that ARGLU1 can shuttle between the 
nucleus and cytoplasm in a cell cycle dependent manner (Sigal et al., 2006).  I would propose an 
experiment in which an inducible ARGLU1 is tagged with a fluorescent protein.  A pulse chase 
experiment could then be performed to track ARGLU1’s cellular localization over time.  
Furthermore, if combined with mutation of the serines in the RS domain, this may be a useful 
system to identify residues important for this nuclear/cytoplasmic shuttling. 
In vitro splicing of ARGLU1 
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It may be of interest to make a smaller splicing reporter that can be used for in vitro 
splicing.  This will be useful for a number of reasons.  It would allow for an analysis of the 
spliceosomal complex at which ARGLU1 splicing is stalled.  However, this type of splicing 
reporter may be hard to construct, as I have shown that a large region of the UCE (approximately 
150 nucleotides) is necessary for intron retention, and in vitro splicing is inefficient across introns 
larger than 250 bases. 
Analysis of the other highly conserved region of the A23 intron 
 Besides the UCE I have investigated in this report, ARGLU1 intron 2 also contains another 
long, highly conserved region (although not as highly conserved as the UCE).  It is possible that 
this sequence also plays a role in ARGLU1 splicing.   
Non-splicing related functions for ARGLU1 UCE 
 I have shown that there are sequences within the ARGLU1 UCE that do not appear to 
function in regulation of ARGLU1 alternative splicing.  It is not immediately clear what the 
function of these sequences is or why they are so highly conserved.  One possible role may be as 
a nuclear rentention signal for the unspliced ARGLU1 RNA.  However, further experiments will 
be needed to understand fully the function of the ARGLU1 UCE.
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Appendix A 
Name Sequence   
ARGLU1 Ex 2.2 GGAAGAAACAGCACGAAGAGT   
ARGLU1 3 UTR R2 GCAGAGCATAGCCCCTATTAGA   
ARGLU1 Exon 2 F TGGTAGCAAAAAGGGTGGAG   
ARGLU1 Exon 3 R CAGTTTGGCTTGTGCTTCTG   
ARGLU1 Exon 4 R ACAGTTTTGGCCTGGACTTC   
ARGLU1 UCE 504 F AATTGTCAACATCTGAATGTTAAGTCC   
ARGLU1 UCE 504 R CTTTAATATCACACAAATCAACAAGG   
ARGLU1 Alt F AAGCTGGCGCGTATGGCAG  
ARGLU1 ret F TTTGGACTGGGAGGGATGA   
ARGLU1 ret R AGGCAGAACCCAACACTGAA   
pcDNA3F TCACTATAGGGAGACCCAAGC   
pcDNA3R CTGATCAGCGAGCTCTAGCA   
Actin F GGACTTCGAGCAAGAGATGG  
Actin R AGCACTGTGTTGGCGTACAG  
   
   
CRISPR sgRNA 
sequences 
   
CRISPR sgRNA 1 AAAGAGGAAGCTGGCGCGTA  
CRISPR sgRNA 2 GCTGGCGCGTATGGCAGCCG  
   
Mutagenesis primers   
  F R 
A23mutAlt3’  CTTCCTGGCGCGTATGGCAGCC GAGATTAAAATGATTTGTACTGTTAGCTTG
GCAATACC 
A23mutAlt5’  GGACAAGACACAAAATATTCAACTTTT
AATGCTGATTAAAG 
AGTGTCCTGCAGAGTGTG 
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SS1 GC-CC  AACTTTTAATCCTGATTAAAGGAGTAT
AG 
GAATATTTACTGTCTTGTCCAG 
SS2 GT-CA  GATTAAAGGACAATAGGTAAAGAATA
CGTAGGTATAC 
AGCATTAAAAGTTGAATATTTACTG 
SS3 GT-CA  AGGAGTATAGCAAAAGAATACGTAGG
TATAC 
TTAATCAGCATTAAAAGTTGAATATTTAC 
SS4 GT-CA  TAAAGAATACCAAGGTATACATAATTG
GTGAG 
CCTATACTCCTTTAATCAGC 
SS5 GT-CA  GAATACGTAGCAATACATAATTGGTGA
G 
TTTACCTATACTCCTTTAATCAG 
SS6 GT-CA  TACATAATTGCAGAGACAAATATTCAC
TTTATTTATATTTTATATATTATTTTTTT
AATTTG 
TACCTACGTATTCTTTACCTATAC 
SS1-3 mut  GACAATAGCAAAAGAATACGTAGGTA
TACATAATTG 
CTTTAATCAGGATTAAAAGTTGAATATTTA
CTGTCTTG 
SS4-6 mut  ATAATTGCAGAGACAAATATTCACTTT
ATTTATATTTTATATATTATTTTTTTAA
TTTG 
GTATTGCTTGGTATTCTTTACCTATACTCCT
TTAATC 
Ex2SS cons aagtCTCGGTCGTTTGGAAAGTAG acctgTCTAGCTTTTTGTGCGGC 
Ex3SS cons cttccagGAGGAAGAACGTGCAAAAC aaagagaATGTTAAGATATTAGAAAAACAAAA
TG 
crp3' cons tccaggagAAGCTGGCGCGTATGGCA agaaagagaGTACTGTTAGCTTGGCAATACCTG 
crp5' cons aagtATTCAACTTTTAATGCTGATTAAAG
G 
acctgCTTGTCCAGTGTCCTGCAG 
  F R 
25 del 1 primers AACATCTGCATTCCTCAG AATTCATCATTCCTAAGGCAAAC 
25 del 2 primers TTCCTTGTATGTTGTTTCTTTATAAATG TATGGTAAGAAGGAACAAAAAATG 
25 del 3 primers ATGGTTGAGCTGCTGATG GGCTGAGCTGAGGAATGC 
25 del 4 primers TGCCAAGCTAACAGTACAAATC TTATAAAGAAACAACATACAAGGAAG 
25 del 5 primers TTAAAGAGGAAGCTGGCG ATACCTGCATCAGCAGCTC 
25 del 6 primers CAGCCGAGGAGCACACTC AATGATTTGTACTGTTAGCTTGGC 
25 del 7 primers CACTGGACAAGACAGTAAATATTCAA
CTTTTAATG 
CCATACGCGCCAGCTTCC 
25 del 8 primers ACTTTTAATGCTGATTAAAGGAGTATA
G 
TCCTGCAGAGTGTGCTCC 
25 del 9 primers TAGGTAAAGAATACGTAGGTATAC TGAATATTTACTGTCTTGTCC 
25 del 10 primers TAATTGGTGAGACAAATATTCAC TACTCCTTTAATCAGCATTAAAAG 
25 del 11 primers TATTTATATTTTATATATTATTTTTTTA
ATTTGGTAAATAC 
TGTATACCTACGTATTCTTTAC 
25 del 12 primers TTAATTTGGTAAATACTATCCAGTTTT
G 
AAGTGAATATTTGTCTCACC 
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25 del 13 primers TTGTAGTTGTCCTTGTTGATTTG AAAAATAATATATAAAATATAAATAAAGT
GAATATTTG 
25 del 14 primers TGATATTAAAGTATTAGTAATAATTGC
CAG 
AACTGGATAGTATTTACCAAATTAAAAAAA
TAATATATAAAATATAAATAAAG 
25 del 15 primers GCCAGGAAACTATCATTAG CACAAATCAACAAGGACAAC 
25 del 16 primers TTTAGTTGGTTGCTGTTTG AATTATTACTAATACTTTAATATCACAC 
UCE del 504 TATTAGTAATAATTGCCAGGAAAC GGAAGGCAGCTTATATTG 
A23ContDel CAAGCCATCAAGCAGTCTTC ACACTCAGGGCTGTAAAG 
A23 168 del 1 AACATCTGCATTCCTCAG GGAAGGCAGCTTATATTG 
A23 168 del 2 ATATTCAACTTTTAATGCTGATTAAAG TATGGTAAGAAGGAACAAAAAATG 
A23 168 del 3 TATTAGTAATAATTGCCAGGAAAC TTACTGTCTTGTCCAGTG 
 
